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ABSTRACT
A critical review of current epidemiological trends and social
science research demonstrates that there is an urgent need for
expanding the range of female-controlled HIV prevention methods.
Existing efforts to control the spread of HIV infection primarily
through the encouragement of a reduction in the number of sexual
partners, widespread condom promotion, and the control of other
sexually transmitted infections are inadequate for many of the
world's women. Underlying gender power inequities severely limit
the ability of many women to protect themselves from HIV infection,
especially in the absence of a prevention technology they can use,
when necessary,
without their partner's consent.
Current
understanding of biology suggests that developing such methods is
a feasible and potentially cost-effective endeavor.
This paper
describes the growing risk of HIV infection faced by women
throughout
the world;
examines the
serious
limitation
of
contemporary AIDS prevention strategy in meeting the needs of
women;
reviews the existing data on female-controlled HIV
prevention methods; and outlines the challenges for future
microbicide development.
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A NOTE CONCERNING TERMINOLOGY
This paper is concerned primarily with the development of femalecontrolled microbicides for intravaginal use in preventing the
heterosexual transmission of the human immunodeficiency virus (HIV) and
other sexually transmitted infections (STI).
In our view, a
microbicidal compound, appropriately formulated to allow women to use
it without the consent of their sexual partners, is the most important
new prevention option to pursue.
In several parts of the text,
however, we apply the cumbersome term "prevention technology" to refer
to the full range of potentially female-controlled methods, including,
most notably, the "female condom" or "vaginal pouch." We review the
data concerning this method, as well as other physical barrier methods,
in Section IV.
In considering the challenges for future development, however, we
focus exclusively on microbicides. Strictly speaking, a "microbicide"
is a substance that "kills microbes" — understood in this paper to
refer to all infectious agents, including bacteria, parasites, and
viruses, and especially, HIV. While an intravaginal compound could
theoretically prevent the transmission of HIV without actually killing
the virus (e.g., by preventing its attachment to the vaginal mucosa),
we do not make this semantic distinction in the text.
For our
purposes, the term "microbicide" refers to any compound capable, when
applied intravaginally, of preventing the transmission of sexually
transmitted pathogens.
It is important to clarify our reasons for using the term
"microbicide" as opposed to the more narrow, but increasingly common,
term "virucide." Frustration with the limitations of the existing AIDS
prevention strategy has generated a search for new prevention options
and, in particular, a female-controlled virucide.
This paper is
predominantly focused on the need for such a compound as an essential
component of a comprehensive response to the AIDS pandemic. In calling
for the resources to pursue the development of new prevention
technologies, however, we must remember that a broad range of sexually
v

transmitted pathogens other than HIV cause considerable morbidity and
mortality among women, especially in the developing world. In view of
this reality, it is obvious that the most desirable compound would be
one that also killed or inactivated the pathogens responsible for other
widely prevalent sexually transmitted infections, such as gonorrhea and
chlamydia. Such a broadly microbicidal compound could be an important
means of preventing the very common problems of pelvic inflammatory
disease, ectopic pregnancy, chronic pelvic pain, and infertility.
There is considerable reason to be hopeful that intravaginal
compounds effective against HIV would have extended activity against
other STIs. Alternatively, virucidal compounds could potentially be
formulated with agents active against the viral, bacterial, and
parasitic organisms that cause other sexually transmitted infections.
The pursuit of "microbicides," therefore, would obviously not exclude
compounds with a specific or narrow range of activity against HIV or
other viruses. We feel that for the purposes of general discussion,
however, the term "virucide" should be used as a specific subset of the
broader term "microbicide." The breadth of the latter term will serve
to remind us of the serious, and largely unattended, problem of
reproductive tract infections among women throughout the world.

INTRODUCTION
Slightly more than a decade after the first recognition of
the AIDS epidemic, the means we have to prevent the spread of HIV
remain remarkably primitive.

We suggest that people not have

sex, or imbue this basic freedom with the burdens of risk and
fear.

We promote condoms as prevention devices without serious

thought concerning their interference with women's childbearing
intentions or the fact that they are male-controlled.

And we

face the embarrassing reality that services to identify and treat
other sexually transmitted infections (now recognized as an
important AIDS prevention tactic) are among the most poorly
funded health-sector programs in both industrialized and
developing countries.

In addition, at present our armamentarium

lacks a critical tool —

a method of HIV prevention that is

within the personal control of women.
Several authors have presented a strong case for developing
such an HIV prevention technology (Stein, 1990; Elias, 1991;
Germain, 1992; Cates and Stone, 1992).

The proponents of such

technology acknowledge the significant and growing risk of HIV
infection faced by women throughout the world and,
simultaneously, recognize the serious limitations of the current
AIDS prevention strategy.

Existing efforts to control the spread

of HIV infection primarily through the encouragement of a
reduction in the number of partners, widespread condom promotion,
and the control of other sexually transmitted infections are
inadequate for many of the world's women (Worth, 1989; Stein,
1990; Ulin, 1992).

Underlying gender power inequities severely

limit the ability of many women to protect themselves from HIV
infection, especially in the absence of a prevention technology
they can use, when necessary, without their partner's consent.
The development of new prevention methods controllable by women
would fill an important gap in the global response to the AIDS
pandemic.
We must be clear, however, that the complexities of AIDS
1

will not be met adequately with a "technological fix." As
outlined in more detail in Section III, efforts to develop
female-controlled prevention options must be complemented by more
concerted attempts to address the underlying gender power
imbalances that shape women's risk of sexually transmitted
infection, as well as their ability to protect themselves using
the currently existing range of prevention strategies.
Although technology development is not a solution in itself,
women's overall vulnerability to HIV would be greatly reduced if
they had access to a prevention method within their personal
control. The absence of a female-controlled method puts women in ■
a uniquely vulnerable position. If men choose to ignore
behavior-change messages to reduce their number of sexual
partners, they still have a technology — condoms — to use to
protect themselves. If injection drug users continue to inject,
they still have a technology — clean needles and/or bleach —
that is both effective and within their personal control. Only
women, who confront centuries of social conditioning that grants
sexual license to men, are expected to protect themselves without
a technology they can control.
Obviously, the development of any additional prevention
technology, including a female-controlled method, will also have
a considerable benefit for men. It is reasonable to assume that
a female-controlled microbicide that afforded women protection
from HIV infection during heterosexual intercourse would also
provide similar, if not greater, protection to men, thus
expanding the options men have for avoiding infection.
Protecting men, obviously, indirectly protects women. Through a
general decrease in sexual transmission, the overall population
of women and men will face a diminished risk of HIV infection.
The advancement of female-controlled prevention technology
will require a long-term commitment to research and development.
This effort will complement current attempts to develop
preventative vaccines. It must be stressed that, despite
remarkable progress in our understanding of the molecular biology
2

of retroviruses, there is no immediate hope for an effective pre
exposure HIV vaccine in humans.

We must, therefore, pursue

jointly both of these important prevention technologies, while
simultaneously addressing the more immediate challenge of
fundamental behavioral change.
We begin our review with a critique of existing AIDS
prevention strategy.

We do not intend to discredit the

importance of this strategy for reducing women's risk of HIV
infection or to portray women as helpless victims.

"Women have

been functioning as actors and prime movers, not just victims, in
response to this epidemic —

not only as activists and

professionals, but also as ordinary women, at the personal level
and in their sexual relationships" (Berer, 1992).

We also do not

argue that resources should be diverted from these efforts to
microbicide research.

It should not be a zero-sum game.

At

present, all AIDS prevention efforts lack sufficient resources to
stop the pace of the epidemic (Funders Concerned About AIDS,
1992) .

Among other things, we need more condoms, lower cost STI

diagnostics, and greater insight into human sexuality and
behavior change.

Microbicide development is a complementary need

arising from the limitations of the current strategies to be
pursued within the broad range of tactics employed by women to
reduce their risk of infection, morbidity, and death.
We do not want to imply that there has been a complete lack
of interest or effort in this area for the past decade.
of important starts have been made.

A number

In the United States, the

United States Agency for International Development (USAID), the
National Institute for Child Health and Human Development
(NICHHD), and the National Institute for Allergy and Infectious
Disease (NIAID) have all invested resources in microbicide
development.

In the United Kingdom, the Medical Research Council

has recently mounted a coordinated research and funding strategy
for the development of intravaginal virucides (Stone, 1992).

We

do want to suggest, however, that this investment has been far
too limited and too exclusively focused on the development of

contraceptive microbicides.

As presented in the text, the

feasibility of developing noncontraceptive microbicides is
unresolved, given our limited knowledge concerning several
critical questions of reproductive biology.

Compared to

contraceptive microbicides, the pursuit of such compounds
presents a number of additional challenges and will most
certainly take a longer time to be realized, but is an essential
goal when viewed from the perspective of women.
To illustrate the level of investment, consider the fiscal
year 1993 contraceptive research and development budget of the
National Institute of Child Health and Human Development (NICHHD,
1993).

While directed research on potentially microbicidal

spermicides represents 20 percent of this budget, the total
dollar amount for such microbicide research is only $1.3 million.
This can be compared to a fiscal year 1992 investment of $43.9
million in government-directed HIV vaccine research by the
National Institute of Allergy and Infectious Disease (NIAID,
1993).

Clearly there is a need for greater investment of

resources in this important topic.
This paper has several objectives:

to describe the growing

risk of HIV infection faced by women throughout the world; to
examine the serious limitations of contemporary AIDS prevention
strategy in meeting the needs of women; to review the existing
data on female-controlled HIV prevention methods; and to outline
the challenges for future microbicide development.

A critical

review of current epidemiological trends and social science
research demonstrates that there is an urgent need for expanding
the range of female-controlled prevention methods.

Current

understanding of biology suggests that developing such methods is
a feasible and potentially cost-effective endeavor.

It is our

hope that by assembling this information in a single review we
will promote a more careful discussion of this vital topic.
Although we have drawn most of our examples from research
concerned with women in developing countries, we believe that the
essence of our argument applies equally as well to poor women in

industrialized countries.
I.

WOMEN AT RISK

The early and persistent stereotype of AIDS as a "gay male"
disease has perpetuated the notion that women are not at risk for
HIV infection. The reality is that in sub-Saharan Africa and
other regions of the world where HIV is predominantly transmitted
through heterosexual intercourse, there are as many infected
women as there are men. As of early 1992, the World Health
Organization (WHO) estimated that over three million women in
sub-Saharan Africa had been infected with HIV, along with onehalf million infants who contracted the virus before, during, or
shortly after birth (Global Programme on AIDS, 1992a). Of the
one million individuals who have contracted HIV in the year since
January 1992, slightly over one-half live in sub-Saharan Africa,
about one-quarter live in Asia and the Pacific, and a little more
than a tenth live in Latin America and the Caribbean (Global
Programme on AIDS, 1992b). Developing countries now account for
over 90 percent of all new infections (Global Programme on AIDS,
1992a).
Surveillance data reveal the degree to which HIV has
penetrated vulnerable female populations. Among female sex
workers, whose contact with multiple sexual partners increases
their risk of having sex with someone who is infected, rates of
HIV infection exceed 50 percent in some urban centers (Table 1).
Rates among sex workers can increase dramatically in a very short
time. In the six months between December 1990 and June 1991, the
seroprevalence of HIV among sex workers in Chiang Mai, Thailand
increased from 22.1 percent to 36.7 percent (Center for
International Research, 1992a; Weniger et al., 1991). For the
year ending June 1991, Thailand's sentinel surveillance system
documented a near doubling of HIV infection among individuals
attending STI clinics in all regions of the country (Center for
International Research, 1992a).
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Table 1:

Percentage of Women Who are HIV Positive,
Selected Countries
Female
Sex Workers

Cameroon
Douala (1989)
Yaounde (1990)
Central African Republic
Bangui (1989)
Congo (1990)
Pointe Noire
Ethiopia (1989)
Addis Ababa
Kenya (1990)
Nairobi
Malawi (1990)
Rwanda (1989)
Kigali
Tanzania
Arusha (1988)
Tanga (1988)
Uganda
Kampala (1990)

Female STI
Patients

Pregnant
Women

10.9
9.3

-

-

17.0

-

8.0

64.1

-

9.0

18.2

36.8

-

87.8
55.9

-

5.8
22 .8

-

-

30.3

75.0
52.6

-

5.5
7.0

—

54.6

34.0 (a)

Zambia (1990)
9-30
71.0
Northern Province
69.0
24.5
Lusaka
India
30.1
New Delhi (1988)
18.1
Bombay (1986)
Haiti (1989)
11.6
Port-au-Prince
41.9
Honduras (1990)
35.0 (b)
a) AIDS surveillance Report Fourth Quarter, 1990. AIDS Control
Programme, Ministry of Health, Kampala, Uganda.
b) Global Programme on AIDS. 1992a. "Current and Future
Dimensions of the HIV/AIDS Pandemic." Document
WHO/GPA/RES/SF1/92.1. p.8.
Source: Center for International Research. "Recent seroprevalence
by country." 1992. Research Note No. 6. Washington, DC: US Bureau
of the Census.
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Sex workers, however, constitute only a small percentage of
the women affected by HIV. Studies show that by 1992, between
one-quarter and one-third of all women aged 15-49 had become
infected in some large urban centers in East and Central Africa
(Global Programme on AIDS, 1992a). While the prevalence of HIV
infection among women is significantly lower in other parts of
the world, the incidence of new infection is increasing rapidly.
In Central America, for example, the number of reported AIDS
cases among women has increased 40-fold in the last four years
(Global Programme on AIDS, 1992a). Not surprisingly, the number
of infants born with HIV is rising in step. In some cities,
between 18 and 32 percent of pregnant women presenting at
prenatal care clinics are HIV-infected (Table 1). Between 15 and
33 percent of the children born to these women will become
infected during pregnancy or birth (European Collaborative Study,
1992; Italian Multicentre Study, 1988). WHO estimates that in
sub-Saharan Africa, infant and child deaths from AIDS may
increase by as much as 50 percent during the 1990s, wiping out
the significant gains in child survival achieved over the past
two decades (Global Programme on AIDS, 1992a).
In industrialized countries, such as the United States and
the nations of Western Europe, the primary populations affected
by HIV continue to be gay and bisexual men and injection drug
users, the majority of whom are male. But here too, women now
comprise the fastest growing population of persons living with
AIDS and HIV infection (Brettle and Leen, 1991). Women are
exposed to the virus through their own use of injectable drugs or
through sexual activity with an infected partner.
According to
1984 figures compiled by the Centers for Disease Control, 6.4
percent of all people diagnosed with AIDS in the United States
were female. By September 1992, this figure had risen to 11.5
percent (Centers for Disease Control, 1992). AIDS became the
leading cause of death for African American women aged 15 to 44
in the states of New York and New Jersey in 1987, and is
7

predicted to become the fifth leading killer of all U.S. women of
reproductive age by the end of 1992 (V. Alexander, 1991).
Worldwide, by the year 2000, the annual number of AIDS cases in
women will equal or exceed the number in men (Petros-Barvazian
and Merson, 1990; and Viravaidya, Obremskey, and Myers, 1991).
A host of biological, cultural, and economic factors
conspire to heighten women's vulnerability to AIDS in comparison
to men's. For example, it is likely that per-exposure
transmission from man to woman during heterosexual intercourse is
significantly more efficient than from woman to man. In one
study of 42 discordant couples* in Nairobi, for example,
Clemetson et al. (1990) found that the rate of transmission from
man to woman was 2.5 times greater than from woman to man. A
comparable study of 563 couples in nine European countries
estimated the risk ratio as 1.9** (European Study Group on
Heterosexual Transmission of HIV, 1992). A greater efficiency of
transmission from man to woman has also been suggested for other
STIs, such as gonorrhea (Hook and Handsfield, 1989).
The efficiency of HIV transmission appears even greater if
the woman or her partner has another sexually transmitted
infection. There is strong evidence that STIs that cause genital
sores, such as herpes, chancroid, and syphilis, can significantly
facilitate the transmission of HIV by creating a site of entry
for the virus (Laga, 1992a; Wasserheit, 1991). Other,
nonulcerative STIs that nonetheless cause inflammation, such as
gonorrhea, chlamydia, and trichomoniasis, may also enhance
susceptibility by concentrating more lymphocytes — target cells
of HIV — in the genital tract (Manoka et al., 1990). Evidence
suggests that the presence of either type of STI increases the
risk of HIV transmission at least 3- to 5- fold (Wasserheit,
1991). Most researchers now believe that the widespread presence

Stable unions where only one partner is infected with HIV.
**(95% confidence interval 1.1 - 3.3)
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of untreated STIs in the developing world may partially explain
why heterosexual intercourse appears to transmit the virus more
efficiently in these regions than in industrialized countries
(Wasserheit, 1991).
Women are at a further biological and social disadvantage
because the same diseases that generally cause burning and
itching in men are often asymptomatic in women, leaving them
unaware that they are in need of treatment (Dixon-Mueller and
Wasserheit, 1991). Researchers estimate that from 10 to 50
percent of women with trichomoniasis, 25 to 30 percent of women
with gonorrhea, and probably over 50 percent of women with
chlamydia and bacterial vaginosis have no symptoms at all
(Wasserheit, 1989) . Others with pelvic pain or vaginal discharge
may accept this discomfort as a woman's "lot in life," not
recognizing that they can and deserve to be treated (DixonMueller and Wasserheit, 1991). Even those who would welcome
treatment often feel too embarrassed or ashamed to seek care at
STI clinics, whose clients are primarily men or female sex
workers (Cates and Stone, 1992). As with health care in general,
women are often too busy, too modest, or too poor to seek
treatment for STIs.
The precarious state of women's reproductive health in the
world's poorer nations also places women at an augmented risk of
infection through increased exposure to blood transfusion. The
lifetime risk of dying from a pregnancy-related cause for third
world women is 200 times that for women in the industrialized
world (Petros-Barvazian and Merson, 1990). Overburdened with
work and exhausted from too many pregnancies and chronic
malnutrition, women in developing countries continue to bear
children and manage their households with little time or energy
left to attend to their own needs. Chronic iron deficiency,
malaria, complicated pregnancies, and lack of access to safe and
legal abortion predispose women to the need for blood

9

transfusion.* While much blood is now tested in the capital
cities of the developing world, adequate quality assurance
procedures are still evolving, and the equipment necessary to
screen blood is often nonfunctional and generally not available
in smaller cities or rural areas.

II.

LIMITATIONS OF THE EXISTING AIDS PREVENTION STRATEGY

As of July 1992, the World Health Organization estimated
that at least 10 to 12 million adults had become infected with
HIV, 75 percent of whom contracted the virus through heterosexual
intercourse (Global Programme on AIDS, 1992b). Among individuals
infected during 1992, over 90 percent acquired their infection
through heterosexual sex. This reflects the continuing trend
toward heterosexual transmission in both the industrialized and
developing worlds. Changing the nature of sexual behavior of men
and women thus becomes a necessary cornerstone of any global
strategy to combat AIDS.
As currently conceived, the global AIDS prevention strategy
consists primarily of three interrelated tactics: 1) encouraging
people to reduce their number of sexual partners; 2) promoting
the widespread use of condoms; and 3) treating concurrent STIs in
populations at risk of HIV. Together, these three themes
constituted the backbone of the $88 million the U.S. government
spent on AIDS prevention in developing countries in fiscal year
1991 (United States Agency for International Development, 1992).
As the following discussion will show, however, this three
pronged attack is inadequate for meeting the protection needs of
many of the world's women. Disproportionately poor and with
little power to negotiate the terms of sexual encounters or to
find livelihoods outside of marriage that do not require sexual
contact, women often cannot avail themselves of these life-saving
Women and children receive roughly 80 percent of all blood
transfused in sub-Saharan Africa (Lamptey and Mitchell, 1990).
10

strategies.

Women need both a new commitment to addressing the

underlying inequities that heighten their risk, and new
technologies that provide them with a means of HIV protection
within their personal control.

A.

Critique of Partner Reduction Strategies
The first line of defense in many AIDS prevention campaigns

has been to counsel individuals to avoid exposure to HIV by
limiting their number of sexual partners.

Teenagers are told to

abstain from sex until marriage, couples are exhorted to remain
monogamous, and others are encouraged, at the very least, to
reduce their number of sexual partners.

There are a number of

realities in women's lives, however, that limit the utility of
this prevention advice.

First, for many of the world's women,

monogamy is a largely irrelevant strategy because they are
already monogamous.

It is the sexual or drug-using behavior of

their sexual partner that puts them at risk.

Second, for a

significant portion of those women who are not monogamous, having
multiple partners is not a pleasure-seeking strategy, but a way
to gain access to resources that only men control.

These women

cannot easily reduce the number of their sexual partners;
multiple partners are their key to survival.

Third, partner-

reduction messages assume that women are always in control of
when they have sex and with whom.

As data on rape and coercive

sexuality indicate, however, this is far from the case in many
sexual encounters.

This section —

which deals with the problems

that partner-reduction messages pose for women —

will examine

each of these issues in turn, exploring how they limit women's
ability to protect themselves from HIV.
The Danger of Reiving on Presumptions of Monogamy
What has been forgotten in the rush to "educate" populations
considered to be at "high risk," such as prostitutes, is that the
mass of women in need of protection are not sex workers, but
11

women with one partner — their husband or the man with whom they
live. In Sao Paulo, Brazil, married women who have only one
sexual partner constitute 49 percent of all new AIDS cases among
women (Pitanguy, 1993). In a recent article from the United
States, Kost and Forrest (1992) review the limited data available
from the General Social Survey and National Survey of Family
Growth concerning reported multiple heterosexual partnership for
men and women and estimate ranges for the direct and indirect
risk of exposure to STIs among reproductive-age women. (Direct
risk of exposure relates to a woman reporting that she has had
multiple sexual partners; indirect risk of exposure relates to
her only male partner having multiple partners.) Even in their
most conservative, low-end estimates, Kost and Forrest find that
women are roughly at equal risk of STI exposure through the
nonmonogamous behavior of their male partner (12.2 percent) as
they are through their own nonmonogamous behavior (14.3 percent).
In the high-end estimates, women are almost twice as likely to
face an indirect risk of STI exposure through their male
partner's sexual behavior (24.4 percent).
Unfortunately, many of the most popular AIDS prevention
messages — "Stick to Your Partner," "Love Faithfully" — give
women the mistaken impression that if they remain monogamous,
they will be safe from HIV. Data from around the world, however,
indicate that it is not safe for women, or for AIDS prevention
programs, to make this presumption. Monogamous women are
increasingly at risk of AIDS through both the heterosexual and
homosexual behavior of their steady male partners. To date, AIDS
prevention programs have not included these women, leaving them
without adequate information or skills to protect themselves from
infection.
Male Infidelity With Women
In many cultures there persists a sexual double standard
that gives men license to be sexually adventurous while
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restricting female sexuality.* As a result, many surveys of
sexual behavior document a higher rate of partner change among
married and single men than among women (Handwerker, 1991;
Sittitrai et al., 1991b; Rwabukwali et al., 1991; and Anarfi,
1992).** In Thailand, for example, 28 percent of a stratified
random sample of men nationwide admitted to having sex outside of
their marriage or steady partnership within the last year,
compared to only one percent of women (Sittitrai et al., 1991b).
Likewise, an island-wide random survey of men and women on
Barbados showed that during the age period 25 to 34, men had five
sexual partners on average, while women had only one. (Not
surprisingly, sticking to one sexual partner did not reduce a
woman's odds of reporting a history of STIs) (Handwerker, 1991).
Results from a six-country, WHO-sponsored survey on African
sexuality found that more than twice as many men as women
reported extramarital affairs in the 12 months prior to the
survey. Men also reported significantly more lifetime sexual
partners (Carael et al., 1990).
A study from Kigali, Rwanda (Allen et al., 1991) illustrates
starkly the danger women face in assuming that monogamy
"protects" them from AIDS. Of 1,458 women aged 18 to 35 years
attending the outpatient pediatric and prenatal clinics at the
Centre Hospitalier de Kigali, 86 percent reported being married
or in a common-law union with a man. All but 10 reported being
monogamous, although only 496 (34 percent) felt certain of the
fidelity of their partners. Overall, 24 percent of women who
thought they were in mutually monogamous relationships were HIV
positive. Even among the two-thirds of women who had only one
*
The following focuses on data from communities where
polygyny is not a formal social institution.
For an evocative
discussion of the influence of formal polygyny on the transmission
of HIV, as well as other STIs, see Frank, 1992.
Some of this difference may be the result of overreporting
of sexual conquests by men and/or underreporting of extramarital
sex by women.
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lifetime partner — their husband — 21 percent were infected.
The authors suggest that it is likely that a good portion of
these women married men who were already infected with HIV. "A
striking finding," they note, "was the high prevalence of
infection among women who had been living with a partner for less
than seven years.” Apparently, men in Kigali become sexually
active several years before they take a wife, and during that
time their sexual partners are a small group of "free women"
(often single mothers) who have many partners. The prevalence of
infection in 1983 among "free women" in another Rwandan city was
88 percent (Clumeck et al., 1985; Allen et al., 1991). "If the
rise in prevalence in this group increased rapidly in one or two
years and peaked in 1982 and 1983," the authors note, "this would
explain the high prevalence of infection in wives whose partners
had premarital sex in 1982 or later."
The tendency for young girls to be partnered with men many
years their senior increases the likelihood that they will be
exposed to HIV (Table 2). This age gap is likely to increase as
older men seek out younger and younger partners in the hopes of
avoiding AIDS — a pattern already documented in parts of Africa
(Amnesty International, 1992). It will also increase as harsh
economic times lengthen the time it takes for African men to
accumulate the "bridewealth" they must pay a woman's family to
secure her hand in marriage (Palloni and Lee, 1990).
Table 2:

Age Difference Between Spouses in Years

COUNTRY

MEDIAN DIFFERENCE

Nigeria
Ghana
Sudan
Bangladesh
_____ Morocco__________________________________

9.7
7.6
8.4
9.1
6. 5____________

Source: Casterline, J., Williams, L. and P. McDonald. 1986.

age difference between spouses: Variations among developing
countries,” Population Studies. 40, 3.
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"The

Mathematical models of the AIDS epidemic show that a woman's
risk of contracting HIV increases dramatically as her age at
first intercourse goes down and/or the age difference between her
and her partner goes up (Palloni and Lee, 1990; Anderson et al.,
1986).

Older men have had more sexual partners and, therefore,

have a greater chance of being infected with HIV or other STIs.
It has also been suggested, however, that early intercourse may
represent an additional, independent, risk (Cates, 1991; Kost and
Forrest, 1992; Moscicki et al., 1989).

Data suggest that if a

young woman is exposed to HIV before genital maturation is
complete, she may face a greatly augmented likelihood of HIV
infection.

This dynamic may account for the very high rates of

clinical AIDS among young women that have been found in areas
where sexual initiation with older men occurs at a very early age
(United Nations Development Programme, 1992).
As the Rwandan example illustrates, in highly infected areas
a young woman's first sexual partner could easily be infected
with HIV, effectively eliminating the utility of advocating
"monogamy" as a means of AIDS control.

These women need

strategies of HIV prevention that they can use throughout their
sexual and reproductive lives.

This reality, and the desire of

most women to bear children, underscores the need for a method of
HIV prevention that will allow conception.
Many women feel incapable of challenging their husband's
infidelity —

to do so places their relationship, their economic

security, and their physical safety at risk.

During focus-group

discussions in Zambia, for example, many women felt powerless
over their partner's sexual behavior.

"I can be faithful to my

husband, but my husband will not be faithful to me," observed one
woman.

"There are very few men who are faithful to their wives"

(Mushingeh, Chama, and Mulikelela, 1991).

Similarly, from a 27-

year-old woman in the Mukono district of Uganda, "My husband has
lost a girlfriend of AIDS and now he is dealing with another
whose husband died of AIDS this year.

So I think I have got the

virus and with time I will get the symptoms" (Moodie et al.,
1991). Likewise, preliminary data from research projects on
women and HIV in India, Brazil, South Africa, and Guatemala,
reveal that an overwhelming number of women report being
monogamous themselves but aware that their partners are not (Rao
Gupta, 1992). These women also express a sense of helplessness
over their inability to change their partner's sexual behavior.
Male Infidelity With Men
Elsewhere, other "low-risk" women are contracting HIV
through the hidden homosexual behavior of their male partners.
To date, this phenomenon has been studied primarily in Latin
America and the Caribbean, although similar patterns are now
being documented in other places, such as Thailand (Sittitrai et
al., 1991a). Because homosexuality is not accepted in many
cultures and the pressure to have children is acute, many men who
engage in homosexual activity nonetheless marry or have steady
female sexual partners. This sets the stage for increasing AIDS
incidence among women and children, a pattern already documented
in Trinidad and Tobago, Brazil, the Dominican Republic, and other
Latin American countries (PAHO, 1988). As of 1991, bisexuality
was the risk factor for 28 percent of AIDS cases among men in
both Brazil and Mexico* (Huang et al., 1992; Valdespino et al.
1991).
Unfortunately, men who engage in bisexual behavior are very
hard to reach with AIDS prevention messages because many do not
consider themselves "gay" or "bisexual." In Brazil, for example,
only men who take the receptive, passive role in anal sex are
considered homosexual; the man who "inserts" is seen as masculine
regardless of the gender of his sexual partner (Parker, 1992).
Research from Rio de Janiero documents that as of 1990,

In the Mexico study an additional 16 percent of cases among
men were listed as "heterosexual," although the authors estimate
that more than 80 percent of these men were really bisexual.
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unprotected penetrative intercourse was still dangerously common
among men having sex with other men, especially among those who
reported sexual contact with both women and men.*

Fully 56

percent of bisexual men had engaged in anal intercourse with a
male partner during the last six months, 43 percent without a
condom.

Of the 100 percent who also had vaginal sex with a

woman, 89 percent did not use a condom with their female partner
(Parker, 1992).

Not surprisingly, the male to female ratio among

reported AIDS cases in Brazil decreased from 30:1 in 1985 to 6:1
in 1991 (Vilela et al.,1992).
These examples emphasize the importance of reaching all
women with AIDS prevention messages, not just those who
themselves engage in "high risk" activity.

In fact, it is

precisely those women who appear least at risk of contracting HIV
—

married women who have no outside partners and do not use

drugs —

who are left exposed due to the failure of most AIDS

prevention campaigns to reach out to women other than those who
identify themselves as sex workers.

Women's risk of HIV is also

exacerbated by the failure of most programs to target men.

As

the epidemic proceeds, sexual partners of men at high risk are
destined to make up an ever larger share of individuals
contracting AIDS.
Sexual Networking as an Economic Strategy
Many partner-reduction messages are based on the premise
that individuals seek multiple partners to further their own
pleasure; reducing one's risk is thus only a question of exerting
self-control.

While pleasure is surely a factor in many cases,

there is also a need to replace partners lost through separation,
divorce, or death.

Likewise, for many women, having more than

Studies from Lima, Peru (Bossio, 1990) and Trinidad and
Tobago (McCombie et al., 1990) also document that bisexual men
report lower levels of perceived self-risk than heterosexual men
and significantly lower levels of condom use with their female
partners compared to their male partners.
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one partner is an economic survival strategy that is central to
their ability to support themselves and their children.
"Stick to One Partner" slogans ask many women living on the
edge to forego income vital to meeting today's needs to avoid an
ill-defined risk of AIDS 10 years hence. Increasing poverty,
especially among women, has made this type of balancing act ever
more present in women's sexual decision-making. In the decade
prior to 1990, three-fourths of the world's women lived in
countries whose per capita gross domestic product either declined
or increased by an average of less than $10 per person annually
(UNDIESA, 1991). With declining real income, women have had to
compensate by working longer hours, competing with men in a labor
market that severely undervalues women's work.
This period of economic deterioration coincided with and
contributed to an unprecedented rise in the number of households
headed by females. Estimates indicate that women are now the
sole earners in one-fourth to one-third of all the world's
households (Agarwal, 1990). Given women's lack of access to wage
employment and their responsibility for child care and family
upkeep, it is not surprising that households headed by women are
disproportionately poor. Data from five Latin American cities,
for example, document that the median monthly income of poor
households headed by women is consistently lower than that of
households headed by men (Arriangada, 1990).
With few marketable skills, many women have come to rely on
"sexual networking"* as an economic strategy to sustain their
families in the face of growing economic uncertainty. Although
the composition of sexual networks varies, research has shown
that women often have relationships with more than one man to
gain access to resources — resources they do not command
themselves because of entrenched gender discrimination in access

"Sexual networking" is a phrase increasingly being applied
by anthropologists and public health experts to describe patterns
of multi-partnered sexual relationships.
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to education, to credit, and to the formal wage economy (Bledsoe,
1990a; Guyer, 1988; Schoepf et al., 1990).

These women cannot

practically "reduce" the number of their sexual partners.
In urban areas of Africa, for example, it is not uncommon
for women to form relatively stable unions with several partners,
each of whom contributes in some way to the maintenance of their
families.

These relationships may and often do involve

affection, but their primary motive is economic.

A woman may

have ties to several long-distance truck drivers, for example,
whom she sees on occasion when they pass through town.

They, in

turn, help buy groceries and pay the school fees for her
children.

These women —

known as "spares" in Zimbabwe,

"deuxiemes bureaux" in Francophone Africa, and "girl friends" or
"town wives" elsewhere in Africa —

draw strong distinctions

between themselves and "prostitutes," making them unlikely to
respond to standard messages linking AIDS with the explicit
exchange of money for sex (Lamptey and Potts, 1990).
Women clerical workers, school girls, and female traders are
examples of the larger population of urban women who often
survive by occasionally bartering sex for the resources and
upward mobility that older men can provide (Ulin, 1992).

It is

quite common for secondary school girls, for example, to take up
with a "sugar daddy" who helps pay the fees and expenses that
allow her to stay in school.

As anthropologist Caroline Bledsoe

explains in her study of urban school girls in Sierra Leone,
girls from poor families have little choice but to seek outside
support if they want to continue their education (Bledsoe,
1990b).

According to Bledsoe, even better-off parents often

hesitate to spend money on school fees for adolescent daughters,
fearing that they will get pregnant early and drop out of school.
"Ironically," she notes, "parental reluctance itself often makes
this outcome a self-fulfilling prophecy."

Each year, thousands

of school girls in Africa are forced to drop out' of school
because they get pregnant as a result of providing sexual favors
to older men in exchange for school money.
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Many of these young

women are then repudiated by their families, forcing them to
engage in more high-risk sexual behavior.

One study of

prostitutes in Nairobi found that the majority were unwed girls
who had dropped out of school due to pregnancy.

The rest were

primarily divorced, separated, or widowed women (Ngugi, 1991).
The Nairobi study is just one among many that demonstrates
that prostitution is often an economic survival strategy,
especially for women who have been ostracized or abandoned by
their husbands, family, or community.

Depending on the culture,

a wide variety of social "transgressions" can precipitate
repudiation —

among them divorce, unwed pregnancy, AIDS,

infertility, widowhood, or surviving a rape.

A study by the

Indian Housewives Federation, for example, found that 80 percent
of New Delhi prostitutes in their sample were women cast out from
their communities after having been raped (Rad, Vaid, and Juneja,
1992).

The migration of abandoned or rejected barren women to

urban prostitution has also been noted in Niger, Uganda, and the
Central African Republic (Frank, 1983).

Ironically, many of

these women are abandoned due to infertility caused by an STI
acquired from their husbands.*
As these examples suggest, cultural and economic constraints
make it difficult for women who have no husbands to survive
without multiple sexual partnerships and the added risk they
entail.

Research in both Uganda and Rwanda, for example, has

shown that women who are separated, widowed, or divorced have
significantly higher levels of HIV infection than do married or
cohabitating women (Allen et al., 1991; Ankrah, 1991).

Although

most women marry early in developing countries, divorce, male
outmigration, widowhood, and abandonment mean that many will have
to survive at least part of their lives on their own.

In Ghana,

for example, the average woman spends 50 percent of her
Studies show that in some parts of sub-Saharan Africa, 30 to
50 percent of women are infertile, compared to the 3 to 7 percent
that would be expected to result from genetic, anatomic, or
endocrinological causes (Wasserheit and Holmes, 1992).
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reproductive years (15-49) without a man in residence (Blanc and
Lloyd, 1990). In some developing countries, more than half of
all marriages will be dissolved by the time a woman reaches her
forties (Table 3). Some of these women will remarry and others
will be supported by an elder son, but many will find themselves
alone with few skills and little education to fall back on. One
researcher estimates that there are roughly 10.5 million widows
in India who are either without adult sons to support them or
have been abandoned entirely by their families (Chen, 1992).
Table 3: Proportion of Ever-Married Women Whose First
______________ Marriage is Dissolved by Age 40-49______________
COUNTRY

PERCENT

Cameroon
Cote D'Ivoire
Ghana
Mauritania

35
45
40
56

Colombia
35
Dominican Republic
53
Haiti
53
Bangladesh
36
Indonesia
55
Malaysia
33
Thailand________________________________________ 27

_______

Source: United Nations. 1987. Fertility Behavior in the
Context of Development. New York: United Nations. As cited in
Bruce, Judith and Lloyd, Cynthia. 1992. "Finding the ties that
bind: Beyond headship and household." Research Division
Working Paper No. 41. New York: Population Council.

Evidence suggests that even among married women, access to
economic resources is often a factor in the decision to take on
additional partners. Among the Yoruba of southwestern Nigeria,
Orubuloye and colleagues found that, in contrast to men, married
women who had affairs seldom said it was for their own pleasure;
rather, it was in exchange for some form of economic assistance
or support withheld by their husbands (Orubuloye, Caldwell, and
Caldwell, 1991).
Likewise, Rwabukwali and colleagues (1991)
argue that among women in Kampala, Uganda, economic necessity was
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the primary reason for sexual risk taking among 72 percent of
HIV+ women and 54 percent of matched controls. Both authors
conclude that sexual networking is in fact a form of economic
networking, making it difficult for women to eliminate outside
partners without access to alternative forms of income.
These examples demonstrate the difficulty of applying
Western categories — "prostitution," "multiple partners,"
"monogamous relationship" — to the reality of third-world
women's lives. Such labels do not begin to capture the subtlety
or fluidity of sexual networks under conditions of economic
scarcity, nor do they acknowledge the degree to which economic
vulnerability shapes the sexual decision-making of third-world
women. Until women have realistic economic alternatives, many
will be unable to heed AIDS prevention messages that advocate
"partner reduction" as a means to protect oneself from AIDS.
The Role of Nonconsensual Sex
Partner reduction messages are only actionable insofar as
women are truly free to control when and with whom they will have
sex. A growing body of literature documents that women are
frequently denied this basic freedom and forced to have
intercourse against their will. The pervasiveness of
nonconsensual sex in women's lives is a reality that prevention
programs have yet to confront, despite its ability to undermine
significantly the effectiveness of conventional AIDS prevention
strategies.
Rape is an extreme example of the type of sexual coercion
that women confront daily in both the industrialized and
developing world. In the United States, for example, populationbased surveys suggest that one in five American women has been
the victim of a completed rape (Koss, in press). Studies
worldwide also demonstrate a remarkable consistency in the
demographics of sexual assault. Contrary to popular perception,
the majority of rape survivors (60 to 78 percent) know their
assailants, a reality confirmed by surveys and service statistics
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from rape crisis centers in Malaysia, Mexico, Panama, Peru, and
the United States (Heise, 1993). Also, a large percentage of
rapes are perpetrated against girls 15 years and under, with a
disturbing percentage of assaults against girls younger than 10
(Table 4).
Unfortunately, evidence indicates that even women in
consensual unions often lack control over the dynamics of their
sexual lives. A study of home-based industrial workers in
Mexico, for example, found that wives' bargaining power in
marriage was lowest in the area of deciding if and when to have
sexual intercourse (Beneria and Roldan, 1987). Studies of
natural family planning in the Philippines, Peru, and Sri Lanka
(Liskin, 1981) and sexual attitudes among women in Guatemala
(DataPro and Associacion Guatemalteca para la Prevencion y
Control de SIDA, 1991) also mention the frequency of forced sex
by men, especially when they arrive home drunk. The summary
document of the Guatemalan focus groups observes, "It is clear
from the replies the women gave...that being forced through
violence to have sex by their partner is not an uncommon
experience for Guatemalan women."
Studies show that the percentage of women who experience
forced sex in marriage is even higher among women who live with
physically abusive men. Whereas 14 percent of U.S. wives report
being raped, the prevalence among battered women is between 33
and 46 percent (Council on Scientific Affairs, 1992).* Reports
from Bolivia and Puerto Rico (Isis International, 1988) estimate
that 58 percent of abused women in these countries have been
raped by their husbands, as have 46 percent of abused women in
Colombia (Profamilia, 1992). When one considers the percentage

*
According to a recent review article in the Journal of the
American Medical Association. "Victims of marital rape suffer many
of the same reactions as other rape victims and are likely to
exhibit particularly severe sequelae, both emotionally and
physically (including very severe depression and suicidality)"
(Council on Scientific Affairs, 1992).
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Table 4

Statistics on Sexual Crimes, Selected Countries8
Percent of
perpetrators
known to victim

Percent of
victims 15
years and under

Percent of
victims 10
years and
under
*0
CO
H

—
Lima, Peru
60
18b
58
Malaysia
68
23
36
Mexico City
67c
—
40
Panama City
63
47
13e
Papua New
—
Guinea
62f
29
United
78
States___________________________________________________
8 Studies include rape and sexual assaults such as attempted
rape and molestation, except for U.S data that includes
only completed rapes.
b Percentage of victims age 6 and younger.
c Data from Carpeta Basica. 1991. Mexico City: Procurador de
Justicia del Distrito Federal de Mexico.
d Percentage of victims age 9 and younger.
e Percentage of victims age 7 and younger.
f Percentage of victims age 17 and younger._________________
Table updated from (Heise, 1993)
Data sources: Malaysia data from (Consumer's Association,
1988); Panama City data from (Perez, 1990); Peru data from
(Portugal, 1988); Papua New Guinea data from (Bradley, 1990);
Mexico City data from (COVAC, 1990); United States data from
(Kilpatrick et al., 1992)._________________________________
of women around the world who live with physically abusive
partners, the true dimensions of sexual coercion in relationships
begins to emerge. As Table 5 shows, in many countries one-third
to one- half of all women have been beaten by their partners,
suggesting that a substantial portion of the world's women have
faced coercive sex as well. Since women have little say over
their partner's sexual behavior outside of marriage, their lack
of control over the sexual encounter within marriage is even more
problematic.
Regrettably, there is ample evidence as well that early
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forced sex is an all-too-common dimension of growing up female.
Especially vulnerable are young girls who are forced to have
intercourse by a male relative or are foisted prematurely into
the world of adult sex after being married off as a child.

In

the Maternity Hospital of Lima, Peru, for example, 90 percent of
young mothers aged 12 to 16 had been raped by their father,
stepfather, or another close relative.*

In Jamaica, 40 percent

Table 5 - Percentage of Women Reporting Physical Abuse, Selected
Countries
o

In Papua New Guinea, 67 percent of rural women and 56
percent of urban women have been victims of wife abuse,
according to a national survey conducted by the PNG Law
Reform Commission (Bradley, 1988) .

o

In a detailed family planning survey of 733 women in the
Kissi district of Kenya, 42 percent said they were beaten
regularly by their husbands (Raikes, 1990).

o

In a random sample of Norwegian gynecological patients, 25
percent of women who had ever lived in a relationship had
been physically and/or sexually abused by their partner
(Schei and Bakketeig, 1989).

o

In a study of 1,388 women seeking services (not related to
violence) at Costa Rica's national child welfare agency, one
in two report being physically abused (Chacon et al., 1992).

o

Colombia's detailed, country-wide Demographic and Health
Survey revealed that one in three women have been
emotionally or verbally abused by their partner, one in five
have been physically abused, and one in ten have been raped
by a partner (Profamilia, 1991).

o

In one study of an Indian village, more than 75 percent of
men from lower caste classes admitted to beating their wives
(Mahajan, 1990).

o

A 1990 study of 1,000 women in the department of
Sacatepequez, Guatemala found that 49 percent have been
physically, sexually or emotionally abused; 74 percent by an
intimate male partner (Castillo et al., 1992).

This figure is quoted in Rape:
Can I Have This Child?, a
booklet published by Movimiento Manuela Ramos, a nongovernmental
women's organization in Lima, Peru.
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of pregnant girls aged 11 to 15 reported the reason for their
first intercourse as "forced" (Allen, 1982) . And in Zaria,
Nigeria, 16 percent of female patients attending one STI clinic
were children under the age of five; another 6 percent were girls
under the age of 15 (Kisekka and Otesanya, 1988).

B. Limitations of Condom Promotion Strategies

Another major thrust of AIDS prevention programs has been
the promotion of condoms as a way to protect oneself from AIDS.
To a large extent, the global effort to increase condom use has
just begun. In many parts of the world high cost, poor quality,
and limited availability impair the implementation of this
important element of AIDS prevention strategy. Greater political
commitment and community leadership are needed to make the use of
condoms widely acceptable to individual men and women throughout
the world. Along with this commitment must come increased
resources for improved condom design, procurement, and
distribution.
As a strategy for women, however, condom promotion has some
major limitations that highlight the need for complementary,
female-controlled, prevention technologies. Condoms are a
technology that women may influence, but ultimately do not
control. This means that women's safety is often predicated on
their ability to "negotiate" condom use with an often unwilling
partner. There are a variety of powerful forces — social,
economic, cultural, and emotional — that limit women's ability
to negotiate successfully on their own behalf.
Obstacles to Proposing Condom Use
For a condom-based strategy to work for women, they must
first feel able to discuss sex and condom use with their partner.
Open communication about sexual matters, however, is not a part
of many relationships. A survey of spousal communication in
Asian countries, for example, found that close to a third of the
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women interviewed in the Philippines never talked to their
husbands about sexual matters, nor did 47 percent in Singapore or
53 percent in Iran (UNESCAP, 1974).

Caldwell and colleagues

(1989) report that frank discussion between partners about sex is
uncommon in many parts of sub-Saharan Africa as well.

Elsewhere,

strong cultural factors work against the open discussion of sex.
In traditional Latina culture, for example, a "good woman" is
expected to be naive about sexual matters; knowledgeable or
assertive women are considered to be "loose" (Maldonado, 1991).
There are also strong emotional barriers that prevent women
from raising the subject of condom use.

Especially in the

context of an ongoing relationship, discussion of condoms often
raises painful issues of fidelity and trust that many women and
men would rather not confront.

In focus-group discussions in

places as diverse as the Caribbean, sub-Saharan Africa, and Sri
Lanka, men and women uniformly said that use of condoms
symbolized distrust between partners, rather than care and
concern (Johns Hopkins School of Hygiene and Public Health,
1990).

Not surprisingly, these beliefs make the discussion of

condom use an emotionally loaded topic, especially in the context
of a valued relationship.
Experience has shown that women also suffer abandonment,
physical abuse, and accusations of infidelity by bringing up
condom use.

The family planning literature documents how for

some men, the desire to use any form of birth control signals a
woman's intentions to be unfaithful.

(Their logic is that

protection against pregnancy allows a woman to be promiscuous.)
Where children are a sign of male virility, a woman's attempt to
use birth control may also be interpreted as an affront to her
partner's masculinity.

In focus-group discussions with women in

Mexico and Peru, for example, many women were afraid to bring up
birth control for fear of being beaten, deserted, or accused of
cheating on their partner (Folch-Lyon, Macorra, and Schearer,
1981; Fort, 1989) .

The connection to infidelity is even stronger

for condoms, which are widely associated with promiscuity,
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prostitution, and disease in many parts of the world.

By

bringing up condom use, women either insinuate their own
infidelity or they implicitly assert the right to protect
themselves from husbands who have outside relationships.

This

assertion may trigger violent reactions.
Raising such issues can be equally as difficult and
threatening for women in industrialized nations.

In 1987, the

National Institutes of Drug Abuse (NIDA) launched a major
research and advocacy initiative to test strategies for reaching
and intervening with two groups of women at high risk of
contracting HIV —

injection drug users (IDUs) and sexual

partners of IDUs (mostly low-income, minority women).
most dramatic findings of the study —

One of the

which included large

surveys and in-depth interviews with 200 women in five cities —
was the prevalence of violence in these women's lives, often at
the hands of a male sexual partner.

"For women in currently

abusive relationships," argues Gloria Weissman, the former
director of the project at NIDA, "the risks of introducing
condoms are very real indeed and may, in fact, be much more
immediate than the risk of contracting HIV.

Telling such women

that they should learn to 'negotiate' with their partners is
neither sensitive nor relevant advice"*(Weissman, 1991) .
Besides fear, complex psychological factors often keep
women from raising the topic of condom use with a partner.

Among

such factors is the tendency of individuals to feel personally
immune from risks that they readily acknowledge for others.

This

type of denial is especially dangerous in the realm of sexuality,
where strong emotions often supersede the tug of reason.

Many a

Based on an evaluation of the original 63 interventions,
NIDA has developed a model AIDS prevention program for women, which
was further tested at five locations during 1992.
The new model
emphasizes women's empowerment, both within relationships and
within society at large, and includes a new research instrument
that examines in detail the nature of women's relationships and the
impact of sexual and physical abuse on women's risk-taking
behavior.
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teenage pregnancy has been born of the belief that only "other
people" get pregnant, or "it can't happen the first time."
Likewise, many a married woman has undoubtedly clung to the
belief that her partner is faithful, even when evidence suggests
the contrary. A study of women's risk perception in Mexico, for
example, found that while two-thirds of women thought married
women should use condoms because Mexican men have affairs, the
vast majority of women did not perceive themselves to be
personally at risk (Del Rio et al., 1991). The understandable
need women have to believe that their partners are faithful works
to their disadvantage, especially in cultures where male
infidelity is the norm.
Difficulties in Gaining Male Compliance
The obstacles to discussing the use of condoms can be
formidable, but even when the issue is raised, women often face
entrenched male resistance to their use. Because women are often
dependent on men economically and socially, they have little
leverage for gaining male compliance (Mushingeh, Chama, and
Mulikelela, 1991). The more limited the options a woman has
outside of a particular relationship or sexual encounter, the
less she can afford to lose her partner or her paying customer.
A woman's cultural conditioning may also limit her ability to
assert dominance in the sexual realm, a domain largely controlled
by men in most parts of the world. Likewise, "negotiating"
condom use requires behaviors, expectations, and attitudes that
are foreign to women who have been socialized to be deferent to
male authority and control. As the consensus statement from the
First International Workshop on Women and AIDS in Africa
observes: "Forces ranging from early childhood training to state
laws governing marriage, divorce, and property rights, prepare
women to defer to their male partners, not to instruct or oppose
them...especially in the context of marriage [quoted in Ulin,
1992] ."
Indeed, it is clear from conversations with women in both
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the industrialized and developing worlds that many feel unable to
influence their partner's behavior with respect to condom use.
In focus-group discussions, women in rural South Africa felt it
was a "waste of time" to bring up condom use with their husbands;
they strongly emphasized the need for a preventive method they
could use without their partner's knowledge (Karim, 1992).
Partners of injection drug-using men in New York City expressed
similar frustration at being made to feel responsible for men's
sexual behavior. "The men decide what is going to happen
sexually," they said. If the staff wanted men to wear condoms,
they would have to talk to the men (Worth, 1989). And in Rwanda,
when women were counseled on HIV infection and encouraged to try
prevention, three-fourths of participants opted for a method that
they could use themselves without their partner's cooperation
(nonoxynol-9 foam or cream). Only one-fourth decided to try
condoms (Allen et al., 1988).
Consistent condom use appears to be difficult to maintain
even with substantial outside support and counseling. In Zaire
couples where one partner had HIV infection needed frequent home
visits as well as clinic counseling to help them use condoms
regularly. Despite intensive counseling, infection or pregnancy
occurred in nearly 10 percent of couples followed for six months
or more (Kamenga et al., 1991). Likewise, in Mexico AIDS
educators found that HIV-infected homosexual men needed at least
three months of weekly support-group sessions to encourage and
sustain condom use (Rossi et al., 1989). These studies suggest
the magnitude of the task women face in negotiating consistent
condom use each and every time they have sex.
This is not to say that all women are powerless in sexual
situations that put them at risk. Kline and colleagues (1992)
report that many of the low-income, minority women they
interviewed in New Jersey were able to exert considerable power
in their relationships by withholding sex if a partner refused to
use condoms. Generally, these women were involved with drugusing men who contributed little to the family's economic
30

support.
Orubuloye and colleagues (1992) also report that among the
Yoruba of southwest Nigeria, women have been able to refuse sex,
without violent reprisal, if their partner is known to be
infected with a traditional STI. (Only 36 percent of women said
they would consider using a condom in place of abstinence). The
authors note that Yoruba women have certain advantages when it
comes to controlling their sexuality? they tend to be financially
independent, their families welcome back wives in cases of
conflict, and they traditionally have had the role of enforcing
abstinence during pregnancy, menstruation, and up to two years
postpartum. Polygamy and a tolerance of male infidelity also
mean that men can seek pleasure elsewhere. The authors note,
however, that refusal is likely to be tolerated only until the
man is treated. Long-term refusal, as would be required by HIV
infection, "would likely result in the husband driving away the
wife...or becoming threatening or violent, in which case the wife
would leave."
Several studies have shown that sex workers seem to have
more leverage than women in the general population when
negotiating condom use, probably because bargaining is already an
explicit part of the sexual encounter and the balance of power is
more equal between buyer and seller. Most peer-education
programs for sex workers have shown that condom use can increase
substantially if women are educated about their risk and taught
how to use condoms properly (Plummer et al., 1988; Monny-Lobe et
al., 1989; Liskin et al., 1989). But here too, women experience
difficulty getting clients to comply. Six separate studies
reported at the Fifth International AIDS Conference found that
the main reason sex workers did not use condoms was male refusal
(Liskin et al., 1989). Even after extensive role-playing
concerning how to overcome client resistance, for example, only
one-third of sex workers in the Dominican Republic were able to
get all 10 of their previous clients to use condoms (Rosaria,
Pareja, and De Lister, 1988).
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As a consequence, many AIDS prevention programs in
developing countries have begun to place greater emphasis on
targeting men. This is a welcome shift from placing all
responsibility for changing male behavior on women. It would be
a mistake, however, to switch entirely away from educating sex
workers and other women to programs targeted exclusively at men,
a response that could evolve from disillusionment over women's
ability to influence their partner's sexual behavior. Such a
wholesale shift would leave women unacceptably exposed. AIDS
prevention programs must reach out to both men and women to be
successful.
Other Impediments to Condom Use
It is not always men, however, that stand between women and
condom use. Among women, the fact that condoms prevent pregnancy
is also a major barrier to their use. In many cultures,
childbearing is a woman's only route to status, and having
children is an important way for women to gain power within the
narrow political realm of the family. Pregnancy is often the
primary motivation for sex: "If a man uses a condom on me, I
cannot even become pregnant, and what is the use of sex without
conceiving?" asked a key informant in the Zambia study cited
above (Mushingeh, Chama, and Mulikelela, 1991). Likewise, in
Kinshasa, Zaire, despite the well-recognized risk of infection,
the desire to have children was the single most common reason
women gave for not using condoms (Panos Institute, 1990).
Also operative in women's resistance to condoms appears to
be the symbolic significance of unprotected sex — a sign of
intimacy with which condoms interfere. One of the strongest and
most consistent findings to emerge from AIDS research to date is
that women and men alike have proven far more willing to use
condoms with prostitutes, clients, or casual sex partners than
with steady lovers or spouses (Handwerker, 1991; Bossio et al.,
1990). Similarly, sex workers who regularly use condoms in their
profession have proven unwilling to introduce them into their
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private lives (Liskin et al., 1989; Worth, 1989; Hooykaas et al.,
1989) .

This appears to be related to the need to distinguish

work or recreational sex from relationships that have more
emotional significance.

In many different contexts,- a

willingness to engage in unprotected sex has become a cultural
marker of intimacy (Cohen, 1989).
Moreover, like men, women can find condoms unpleasant
because they reduce sensation and interfere with notions of
spontaneous or "natural" sex (Kline, Kline, and Oken, 1992;
Mushingeh, Chama, and Mulikelela, 1991; Del Rio et al., 1991).
As one female informant noted in the study of sexuality among
fish traders in northwestern Zambia: "If there is no sperm, I
can't enjoy sex.

If I am in love with you, I have also accepted

the risk of disease - even death" (Mushingeh, Chama, and
Mulikelela, 1991) .

Similar concerns about interrupting the

passionate flow of lovemaking have been mentioned by low-income,
minority women in the United States (Kline, Kline, and Oken,
1992) .

Elsewhere, female sex workers have expressed dislike for

condoms because they prolong intercourse, which can lead to
painful and dangerous friction sores (Pyne, 1992).

Clearly, a

"condom-only" approach to AIDS prevention must overcome
resistance on the part of both women and men.

c.

STI Control as an AIDS Prevention Strategy
Recently, the strategy of preventing and controlling other

sexually transmitted infections has been accepted as a major
component of the global AIDS response.

After considerable

debate, most researchers now agree that STIs, particularly
genital ulcer diseases, significantly augment the sexual
transmission of HIV (Laga, 1992a).

In fact, a recent review

suggests that, on a population basis, much of the risk of HIV
transmission in Africa may be attributable to the presence of
other STIs (Berkley, 1991).

Many programs have thus come to see

STI control as a priority public health intervention in the fight
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against AIDS.
Prior to the AIDS era, STI control programs were among the
most poorly funded of all health-sector activities.
Strengthening district, state, and national STI control programs
will require additional resources to train providers, establish
diagnostic facilities, and develop clinical infrastructure.
Given these challenges and existing resource constraints, initial
efforts at improved STI control have been highly targeted,
concentrating primarily on "core" groups, such as sex workers,
their clients, and men with repeated STIs. A programmatic bias
toward targeting has been reinforced by econometric modeling that
suggests that targeted interventions are considerably more costeffective (in terms of "healthy years of life saved") than broadbased efforts aimed at the general population (Over and Piot,
1992) . In keeping with this logic, the bulk of STI investment
has gone toward improving the existing network of STI clinics
(whose clientele are primarily men and, in some settings, sex
workers) and establishing new services for reaching these core
groups.*
While such highly targeted efforts may make sense in the
short term, given existing resource constraints, the long-term
reproductive health of women and men depends on a commitment to
promote an expanded development budget that affords reproductive
health services, including routine STI screening and treatment,
the priority it deserves (Sewell et al., 1992). Ideally, STI
services for women in the general population will need to be
integrated with other health services, because women are seldom
*An interesting and potentially important exception to this
rule is the innovative strategy of providing STI treatment through
social-marketing approaches currently being initiated by Population
Services International (PSI).
In a demonstration project in
Cameroon, PSI is developing an STI "kit" containing antibiotics,
educational materials, and condoms, which will be marketed for men
through existing private-sector distribution channels. These kits
will include information regarding the need to refer female
partners
for
clinical
evaluation
(Population
Services
International, 1992a).
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willing to endure the stigma attached to attending an "STI
clinic."

The development of integrated services, in turn, will

require reorientation of service providers, improved clinical
facilities, and practical research aimed at identifying effective
and sustainable service models (Elias, 1991).
As outlined in the proceedings of a recent meeting on
reproductive tract infections,* cosponsored by the International
Women's Health Coalition and the Rockefeller Foundation, the
establishment of adequate services for the recognition and
appropriate treatment of STIs in women will require a significant
investment of resources (Germain, 1991).

This investment is

essential, given the considerable morbidity and mortality that
women experience as a result of these infections.

While the AIDS

epidemic has attracted global attention, in most parts of the
world reproductive tract infections caused by pathogens other
than HIV still account for the bulk of reproductive morbidity
suffered by women (Wasserheit, 1989; Liskin, 1992).
Given the current economic and political climate, however,
it appears unlikely that governments will commit to the type of
expanded budget that would allow for the development of
comprehensive reproductive health services capable of reaching
the majority of the world's women.

As a result, it is unlikely

that most women will directly benefit in the short term from the
"STI control" measures currently promoted as part of the global
AIDS prevention strategy.
This reality creates an even greater urgency to develop

*The term "reproductive tract infection" refers to sexually
transmitted infections of the female reproductive tract, infections
that may be transmitted nonsexually (such as those caused by the
overgrowth of organisms normally found in the genital tract of
healthy women — e.g., bacterial vaginosis and candidiasis), and
iatrogenic infections (such as those caused by unsterile abortion
and delivery procedures).
Given that sexually and nonsexually
transmitted infections of the reproductive tract often present with
similar clinical syndromes (e.g. vaginal discharge, itching, or
lower abdominal pain), the broader term more accurately describes
women's need for clinical services.
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effective microbicides that can be made widely available through
commercial channels. Of course, political pressure must be
maintained on both fronts — to develop microbicides and to
increase greatly national and international funding for
reproductive health services. After all, the unacceptable state
of women's health services and the "orphan" status of microbicide
development result from the same underlying dynamic — a
development agenda that is not sufficiently considerate of
women1s needs.

III.

STRENGTHENING WOMEN'S ABILITY TO PROTECT THEMSELVES

As the previous section demonstrates, the existing
strategies for AIDS prevention are of limited utility to many of
the world's women. Women often have too little power within
their relationships to insist on condom use, and they have too
little power outside of these relationships to abandon
partnerships that put them at risk. What can then be done to
reduce women1s risk?
Ultimately, empowering women to have more control over their
sexual lives will require a fundamental change in the dynamics of
male/female relations and a concerted effort to eliminate the
inequities that leave women economically dependent on men. In
large measure, women's vulnerability to HIV infection derives
from their low status in society. Reducing their vulnerability
will mean changing the cultural beliefs and gender stereotypes
that perpetuate the belief that women are inferior to men.
Empowering women will also require redefining what it means
to be male. In many societies, the right to dominate women is
considered the essence of maleness itself. Culturally created
norms tolerate, indeed encourage, sexual behavior by men that
puts both them and their partners at risk. New norms must be
established — through education and advocacy — that stress
mutuality, responsibility, and equality between men and women.
By its very nature, however, this type of fundamental social
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change takes time — time that women at risk of HIV today do not
have. The AIDS epidemic therefore creates two imperatives: to
begin in earnest to work on changing the underlying causes of
women's vulnerability and to pursue vigorously every means
possible to strengthen women's immediate ability to protect
themselves in the face of the economic and cultural forces that
are currently allied against them. This latter mandate, in turn,
involves two priority tasks: 1) placing a greater emphasis within
existing AIDS programs on empowering women; and 2) developing HIV
prevention technology that is within the personal control of
women.
A.

Long-Term Approaches to Reduce Women's Vulnerability

Advocates working toward women's empowerment have come to
distinguish between efforts that address women's strategic gender
needs (i.e. those that seek to transform society and male/female
relations) and women's practical gender needs (i.e. what women
need for survival today given the reality of their roles and
status) (Moser, 1989). Constructive social change requires both,
as does any effort to respond to the AIDS prevention needs of
women. The limitations of the existing AIDS prevention
strategies, described above, argue strongly for the development
of a female-controlled prevention method. Without a concomitant
dedication to addressing the inequalities that underlie women's
risk, however, a new prevention technology could become a
"technological fix" that allows male dominance to continue
unchallenged. It is important to remember that it is women's
subordination that is their primary risk factor for HIV (Hamblin
and Reid, 1991) .
Strategic efforts toward establishing gender equality are
many, including the revision of laws and labor codes to guarantee
women the right to own and inherit property, earn salaries on a
par with men, and have equal access to credit and training.
These efforts also include promoting female education, educating
women concerning their rights., changing the cultural beliefs and
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biases that denigrate women and value boy children over girls,
and helping women organize on their own behalf. Until women
become part of the dialogue that establishes policy and
distributes resources, women's issues will remain vastly
underattended. And until women share power more equally with men
— in both the public and the private sphere — they will remain
at heightened risk of AIDS.
B.

Changing Current Programs to Strengthen Women's Position

Short of transformational change, there is much that can be
done to empower women within existing AIDS prevention programs.
Promising projects in Thailand, the Dominican Republic, and
Nigeria, for example, have helped sex workers enforce condom use
by improving their assertion and negotiation skills, implementing
"condom-only" policies in brothels, and giving women more power
through self-organization (Bruyn, 1992). A project in Calabar,
Nigeria has helped sex workers change the basic economics of
their trade (Buchan, 1992). Together, these women decided to
raise their fee for sex simultaneously so that they could afford
to refuse clients who would not use condoms. Project organizers
also persuaded hotel owners not to raise the price of the rooms
that the women use for clients, arguing that "safe sex" was in
the owner's long-term financial interest. The project, which was
started by a group of volunteers, is now largely self-supporting,
with the women themselves taking over most of the organizing
functions.
The key to the Calabar project's success is that it built
upon women's capacity for collective action. Women throughout
the world have a history of rallying together to solve common
problems — a strength that has yet to be widely utilized by AIDS
prevention programs. As behavioral scientist, Priscilla Ulin
(1992), observes, "Women's collective perception of their ability
to act on AIDS prevention messages could be a critical
determinant of both male and female behavior change." To date,
there has been little effort to initiate dialogue among women
38

about the strategies they have used successfully to change their
own or their partners' behavior. Nor have most projects sought
to organize women to exert collective pressure on men to change
their ways. Examples abound, however, of instances where,
through collective action, women have managed to affect and
change male behavior (e.g., successful campaigns against male
alcoholism in India and community policing against wife battering
in Peru) (Kanhere, 1980; Isis International, 1987).
Elsewhere, projects that seek to empower women have learned
that it is impossible to deal with a woman's HIV risk divorced
from the other issues in her life — relationship problems, drug
use, lack of job skills. Groups like PROTOTYPES in Los Angeles
and AWARE in San Francisco help women take charge of their lives
one step at a time. PROTOTYPES, for example, uses peer educators
— other women who have turned their lives around — to reach out
to injection drug-using women and partners of injection drug .
users (Reback, 1992). Women are invited to join the project's
program, which includes six months of one-on-one counseling, as
well as group workshops that allow women to share experiences,
build self-esteem, and learn new skills through role plays.
Recognizing that HIV risk is exacerbated by underlying
dependencies, PROTOTYPES also runs a residential program where
women can live with their children for up to a year and receive
drug treatment and vocational training in computer science.
The AWARE program also uses peer counselors, but they work
on the streets in poor neighborhoods. The program provides
special support, health and sex education, and free comprehensive
health examinations. Staff also provide referrals and advocacy
for women needing access to specialized health care and other
treatment programs. Although many of AWARE's participants have
remained in high-risk relationships, their ability to use safer
sex practices has significantly increased, and, as of 1992, only
one woman had become infected with HIV since the program began in
1986 (Dorfman, Derish, and Cohen, 1992).
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C.

Developing New Prevention Technologies

The challenge of microbicide development is historically
analogous to the development of female-controlled contraceptive
technology 40 years ago. Although the development of femalecontrolled methods, like the pill, was not sufficient in itself
to address women's need to control their fertility
comprehensively, it did provide an essential tool that allowed
many women to reduce their risk of unwanted pregnancy.
There are many important lessons from contraceptive
development that bear on the search for new HIV prevention
technologies. One is the general principle that increasing the
range of contraceptive methods available to women improves
overall use (Jain, 1989). In family planning, expanded method
choice affects use both by recruiting new users and by
facilitating the continuation of contraceptive use over time.*
The availability of multiple methods means that more women will
find at least one that meets their particular needs.
A similar dynamic can be expected to apply to technologies
for the prevention of HIV. Women differ in terms of their
childbearing aspirations and the nature of their sexual
relationships. Even within a single relationship, sexual
encounters may vary across time (i.e., from voluntary, consensual
intercourse to violent, coercive sex when a partner arrives home
drunk). All of these variables affect the type of prevention
method that may work for a woman in a particular setting. As
*
In a recent review of the literature, Jain (1989) found
that the widespread addition of one new method of contraception to
a country's family planning program increased the number of couples
practicing contraception by 12 percent.
In addition, data from
Bangladesh show that two-thirds of women still practicing
contraception 18 months after acceptance had switched methods
(Bhatia et al., 1980). In the Philippines, 34 percent of acceptors
still contracepting at 24 months had switched methods at least once
(Laing and Alcantara, 1980). Women switched methods because of
unpleasant side effects or because their life circumstances
changed.
If alternative methods had not been available to
accommodate these changes, many women would likely have
discontinued family planning altogether.
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with avoiding unwanted pregnancy, we must recognize that the
sexual encounter is the most relevant focus for prevention
strategies.

In many cases this is more important than a more

general focus of "high-risk" relationships.

Whereas a condom may

be used for some encounters or with some partners, other
situations may require more secrecy.

Indeed, for many

nonconsensual encounters, a method that can be used after
intercourse might be required.

As with contraceptive choice, the

availability of multiple methods would help ensure that at any
given time, at least one method would be available and be used
(Bruce, 1990).
Another important lesson from the history of contraception
is that new technologies, especially when they are the first of
their kind, have a capacity to help crystallize social movements.
The introduction of "the pill" in the early 60s helped to usher
in and validate a whole generation of new expectations.

As the

first simple and effective female-controlled contraceptive,

it

assisted in bringing about and consolidating social discussion of
women's entitlement to control their own fertility.

An important

role of technology in a postmodern society is to focus social
discourse.
In the area of AIDS prevention, the introduction of a
female-controlled technology could serve a similar function,
focusing attention on the protection needs of wives and
adolescent girls.

As discussed in the foregoing sections, many

AIDS prevention programs have focused almost exclusively on sex
workers and, more recently, their clients.

The failure to reach

out to other women does not necessarily reflect a lack of
concern; rather, it derives from a profound pessimism regarding
women's ability to change the behavior of their sexual partners.
In short, current programs take women's powerlessness as a given,
and therefore fail to include them.

The availability of a

female-controlled microbicide, however, would incite a discussion
regarding its use and accessibility by all women, thus creating
an incentive and a demand to throw the prevention net more
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widely. In this way, rather than being a substitute for the
empowerment of women, a new technology might be a tool for such
empowerment.
A final lesson from the contraception field returns us to
the first point of this section. Practical solutions to women's
vulnerability cannot be pursued in isolation from the longer term
strategic needs of women for societal change. Several decades
after the development of highly effective female-controlled
contraceptive technologies, many of the world's women remain at
risk of unwanted pregnancy and its complications. This reality
reflects a lack of political will to invest in health care, to
improve the status of women, and to make abortion legal and safe,
as well as an often too-narrow focus on the introduction of new
technology without adequate attention to provider training,
client education, and the development of appropriate counseling
services. Similarly, a female-controlled microbicide will not be
a "magic bullet" that eliminates the need for fundamental social
change.
A technology for women, however, is an essential
element of any viable global response to AIDS.
IV. FEMALE-CONTROLLED HIV PREVENTION TECHNOLOGY: CURRENT OPTIONS

Most women are at greatest risk of acquiring HIV infection
through heterosexual vaginal intercourse with an infected man.*
To avoid infection a prevention method must establish an
effective barrier between the infectious elements in the male
*
On a per-exposure basis, unprotected anal intercourse
appears to be more likely than vaginal intercourse to result in HIV
transmission from man to woman (European Study Group, 1992). Anal
intercourse is a common sexual practice among homosexual men, as
well as heterosexual men and women (Bolling, 1977) .
In some
communities it is commonly substituted for vaginal intercourse as
a means of fertility regulation. Given very different biological
considerations (for example, radical differences in pH and normal
flora), potential microbicides would have to be separately
formulated and evaluated for safe use intrarectally. Although we
do not address the biology or clinical testing of rectal
preparations in this paper, we recognize that this is an extremely
important area for future research.
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genital secretions/ejaculate and those cells of the female
reproductive tract susceptible to infection.

Such a barrier

might be physical (such as that provided by condoms), chemical
(such as that provided by an intravaginal microbicide), or
immunological (such as the mucosal immunity that might result
from an effective vaccine).

Ideally, such a barrier would be

selective, providing effective protection against HIV and other
sexually transmitted infections without impairing a woman's
ability to conceive.

Such an ideal barrier could be combined

with a spermicide (or another method of birth control) for use
when contraception was explicitly desired.
As discussed below, a large number of unanswered questions
remain regarding the biology of heterosexual HIV transmission.
For example, does transmission result from the free virus or
cell-associated virus found in semen?

Which cells in the female

reproductive tract are most susceptible to infection?
mucosal cells susceptible?

Are all

What is the role of vaginal pH?

Answers to these and other questions are needed to define more
precisely the required characteristics of ah effective barrier,
as well as the feasibility of identifying methods that are
noncontraceptive.

This section reviews the current, somewhat

limited, state of knowledge regarding existing female-controlled
options for preventing the sexual transmission of HIV infection.
The subsequent section outlines the major issues and challenges
to be faced in broadening women's options for exercising personal
control over their risk of HIV infection.

A. The "Effectiveness" of Female-Controlled Prevention Methods
One might assume that a vaginal microbicide —
barrier —

a chemical

would be less efficacious in preventing HIV

transmission than a condom —

an impermeable physical barrier.

But when considering HIV protection, it is important to
distinguish between the theoretical effectiveness of a method and
the level of protection it achieves in real life.
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As in the case

of contraceptives, an HIV prevention technology that is highly
efficacious in the laboratory may be only moderately effective in
preventing transmission, because couples fail to use it properly
or consistently.

Even the best barrier cannot prevent infection

if it is not used.
This distinction —

known in the contraceptive field as the

difference between "theoretical effectiveness" and "use
effectiveness" —
prevention.*

has important implications for AIDS

Under ideal conditions, for example, condoms have

been shown to be highly effective physical barriers for
preventing the transmission of a wide range of sexually
transmitted pathogens, including HIV.

In other words, condoms

appear to have a high theoretical effectiveness (Centers for
Disease Control, 1988; Rietmeijer et al., 1988).

Under actual

use, however, there is reason to believe that condoms might be
less effective in preventing HIV transmission, despite their
higher theoretical effectiveness, than would female-controlled
methods.

By virtue of being female-controlled, methods such as

contraceptive sponges and vaginal spermicides have the potential

to be used in a greater percentage of sexual encounters, thereby
achieving a greater long-term use effectiveness than condoms
(Stein, 1990).
Indeed, the results of a recent retrospective study of STI
transmission in a Denver STI clinic reflect just such a
conclusion (Rosenberg et al., 1992).

Employing a comparison

group consisting of women using no contraceptive or with tubal
ligations, Rosenberg et al. compared the rates of reproductive
tract infection among users of condoms, diaphragms, and sponges
as a means of contraception.

Users of all three barrier methods

Theoretical effectiveness refers to the effectiveness of a
particular method when used perfectly. Use effectiveness refers to
a method's effectiveness under real life conditions and reflects
failure to use the method, as well as its inherent limitations. In
epidemiological terms, theoretical effectiveness refers to a
method's efficacy.
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had lower rates of infection with Neisseria aonorrhoeae.
Trichomonas vaginalis, and Chlamvdia trachomatis when compared to
controls.* More significantly, users of sponges and diaphragms
had a lower risk of gonorrhea and trichomoniasis than did condom
users, even after adjusting for age, race, partner exposure,
symptoms, and history of prior STI. The adjusted odds ratios
were 0.45 [95% G.I. 0.22 - 0.92] and 0.33 [95% C.I. 0.17 - 0.64],
respectively. While the Denver study did not address HIV
infection directly, its findings provide strong circumstantial
evidence that a female-controlled microbicide would play a
significant role in averting such infection, even if it were less
efficacious than condoms on a per-exposure basis (i.e., had a
lower theoretical effectiveness). This dynamic would be most
prominent among vulnerable women who are least able to negotiate
condom use with their partners.
Another retrospective study among U.S. prostitutes showed
that use of a spermicide and/or diaphragm was associated with a
markedly decreased risk of Hepatitis B virus (HBV) infection in
some groups of women, specifically black and Hispanic IDU sex
workers (Rosenblum et al., 1992). This association was not found
in all groups of sexually active women at risk of HBV infection,
however. Also, in a recent prospective randomized controlled
trial, although the use of spermicide containing nonoxynol-9 was
found to be protective against cervical infection, this effect
was only noted in women with >75 percent compliance (Niruthisard,
Roddy, and Chutivongse, 1992). In the same study, condom use was
found to be partially protective at lower levels of compliance.
The strengths and weaknesses of these findings, along with
conflicting views regarding their public policy implications,
have recently been presented in a series of commentaries in the
American Journal of Public Health (Stein, 1992; Rosenberg and

These lower rates reached statistical significance only for
N. gonorrhoeae
and T. vaginalis, given the generally low
incidence of C. trachomatis infection.
45

Gollub, 1992; Cates, Stewart, and Trussel, 1992).
B. The "Vaginal Pouch" or "Female Condom"

One new technology designed to expand women's options for
preventing HIV infection is the "vaginal pouch" or "female
condom," now available in Switzerland and the United Kingdom.
There are currently three such products, including two latex
devices and a polyurethane sheath. The vaginal sheath (to be
marketed as Reality® in the U.S. and Canada and as Femidom® in
other countries) has received the most extensive evaluation to
date (Bounds, Guillebaud, and Newman, 1992; Liskin and
Sakondhavat, 1992). This sheath is made of soft polyurethane
with a flexible ring at each end. The smaller ring is used for
insertion, much like a diaphragm, but without the need for
individual fitting. The larger, more flexible, ring hangs
outside the vagina (Townsend, 1991).
Like the male condom, the vaginal sheath attempts to prevent
HIV infection by providing an impermeable physical barrier.
Indeed, by providing more complete coverage of the vulva, this
device may theoretically provide greater protection than standard
male condoms. While the vaginal sheath has been shown to be
impermeable to HIV in laboratory testing (Drew et al., 1990;
Leeper, 1990), there are yet no clinical data that evaluate its
effectiveness in preventing HIV transmission in real life
(Feldblum and Fortney, 1988). Initial studies indicate that its
use effectiveness as a contraceptive method is comparable to that
of the male condom (Trussel and Kost, 1987). In a recent study,
100 self-selected women used the device as their sole method of
contraception for 437 person-months of observation and had a
failure rate of 15 percent at 12 months (Bounds, Guillebaud, and
Newman, 1992). There were seven conceptions, of which four were
associated with inconsistent use. The remaining three appeared
to be true method failures.
Preliminary field trials have also shown the vaginal pouch
to be effective in preventing the transmission of some common
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STIs (Shangold, in press). In one trial, women were given the
female condom and instructed in its use following treatment for
trichomonas or chlamydia. Consistent users showed substantially
lower reinfection rates than did intermittent or nonusers. This
study, together with the laboratory data and the results of the
contraception trials, suggest that the female condom will serve
as a reliable barrier to HIV and other sexually transmitted
pathogens. In December 1992, an advisory committee of the U.S.
Food and Drug Administration recommended that the device be
approved for use in the U.S. with labeling indicating it has the
potential to prevent both pregnancy and sexually transmitted
infection (Wisconsin Pharmacal, 1992).
Despite this high theoretical effectiveness, there are
several reasons to doubt whether the vaginal sheath will greatly
expand women's control over their HIV infection risk.
Acceptability studies have shown that a substantial number of
users (both male and female) indicated that they would use the
method again, but the majority stated a preference for male
condoms (Liskin and Sakondhavat, 1992). Men and women cited
physical discomfort during intercourse, objectionable noise,
slippage into the vagina, and unaesthetic appearance as barriers
to use. Moreover, because the female condom still requires male
cooperation and consent, it does not fulfill women's need for a
surreptitious method. In the Kenya acceptability study, men's
objections were the major reasons why 40 percent of the women
discontinued use after the first three weeks of the study
(Ruminjo and Steiner, 1991) . The investigators of the largest
acceptability study, conducted in the United Kingdom, concluded
that "although the majority of study participants did not find
the product acceptable, we can confirm the existence of a sub
population of sexually active couples who like this new
contraceptive and if it were available would continue to use it"
(Bounds, Guillebaud, and Newman, 1992).
Beyond the acceptability issues, concern exists that the
projected cost of the sheath will make it unavailable to the
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majority of the world's women. When it comes to market in the
U.S., Reality® will be priced in the range of $2.00 to $2.25 per
sheath, more than three times the current price of male condoms.
The cost of this method will be prohibitive to most women,
especially in developing countries, unless a substantially
reduced public-sector price can be negotiated. Public subsidies
of this new method, however, will have to be balanced directly
against the current needs for expanding the procurement and
distribution of male condoms.
An additional concern relates to the still unquantified risk
associated with reuse of the female condom, a possibility made
more likely by its high cost, as well as the greater durability
of the thicker polyurethane sheaths compared to typical latex
male condoms. A small minority of women in the acceptability
studies reported reusing the sheath, including some sex workers
who did not clean the sheath between clients (Monny-Lobe and
Joanis, 1991; Ruminjo and Steiner, 1991). There are currently no
data on breakage rates associated with reuse of the product or on
the risk of facilitating STI transmission in the absence of
careful washing (Liskin and Sakondhavat, 1992).
In conclusion, it is clear that the female condom is not the
final answer to women's need for an expanded range of HIV
prevention technologies. This device is female-applied; however,
because male consent and cooperation are required, for many women
it will not be sufficiently "female-controlled." Neverless, for
a small subpopulation of women and couples, it may provide an
additional, acceptable method of protection against both unwanted
pregnancy and sexually transmitted infection. Given the limited
options currently available for these purposes, the importance of
this incremental addition to the range of HIV prevention
technologies should not be understated. In addition, it must be
remembered that the current devices are essentially prototypes
and, therefore, there is still much room for improvement in
design. Subsequent generations of vaginal sheaths may prove
acceptable to a broader range of women and couples.
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C. The Controversy over Nonoxynol-9
At present there are only two spermicides approved for use
in the United States, nonoxynol-9 and octoxynol-9.

Nonoxynol-9

is the active ingredient in the vast majority of over-the-counter
contraceptive products, including diaphragm jelly, vaginal
suppositories, and the Today® sponge.

Since the early days of

the AIDS epidemic, public health workers have suspected that
nonoxynol-9 in its various preparations might offer some
protection against HIV infection.

Researchers have shown that

nonoxynol-9 kills a wide variety of STI pathogens in vitro.
including HIV (Alexander, 1990; Hicks et al., 1985; Voeller,
1986; Malkovsky, Newell, and Dalgeish, 1988).

Like other

"biodetergent" compounds, nonoxynol-9 acts by indiscriminately
disrupting cell membranes and viral envelopes.

It remains

unclear, however, whether the demonstrated virucidal action of
nonoxynol-9 in the laboratory translates into reduced
transmission of HIV to women during actual sexual intercourse.
There is considerable circumstantial evidence to suggest
that nonoxynol-9 has the potential to provide women some
protection from HIV.

Nonoxynol-9 has been shown in a number of

clinical trials, for example, to reduce the sexual transmission
of common bacterial STIs, such as gonorrhea and chlamydia (Louv
et al., 1988; Rosenberg et al., 1987; Niruthisard et al., 1991;
Washington, Cates, and Wasserheit, 1991).

Clinical trials of the

Today® sponge, as well as spermicidal jelly, have reported
reductions of 10 to 69 percent for gonorrhea and 25 to 40 percent
for chlamydia (Rosenberg and Gollub, 1992; Centers for Disease
Control, 1988; North, 1990).

Other research shows that a woman

can significantly augment her protection from these common STI
pathogens by using a diaphragm in conjunction with nonoxynol-9
(Rosenberg and Gollub, 1992; Alexander, 1990; Cates and Stone,
1992).

In one study, nonoxynol-9 plus a diaphragm reduced the

incidence of gonorrhea by 55 percent as compared to a 10 percent
reduction with the spermicide alone (Austin, Louv, and Alexander,
1984) .

The added efficacy of a physical cervical barrier makes
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sense in the case of gonorrhea and chlamydia, because both
pathogens infect the cervix primarily.
The relevance of these findings for HIV remains unclear,
however, since different pathogens have different mechanisms of
infection. For example, the role of the cervix in HIV
transmission has yet to be defined precisely (Alexander, 1990).
Compared to its demonstrated clinical efficacy in preventing
gonorrheal and chlamydial infection, the ability of nonoxynol-9
to prevent other reproductive tract infections (including viral
infections other than HIV) is less well established (Barbone et
al., 1990). As mentioned above, a retrospective study of factors
affecting the sexual acquisition of Hepatitis B virus revealed a
beneficial effect from nonoxynol-9 in only some groups of at-risk
women (Rosenblum et al., 1992). It has also been suggested that
nonoxynol-9 may reduce a woman's risk of developing cervical
cancer, a disease associated with certain strains of the human
papilloma virus and widely considered to be sexually transmitted
(Peters et al., 1986). Likewise, in animal models, researchers
have shown that nonoxynol-9 applied intravaginally in macaque
monkeys can provide at least partial protection against infection
with the simian immunodeficiency virus (SIV), an animal
retrovirus. In one experiment, only 7 out of 12 female macaques
became infected after receiving almost 1000 times the viral load
normally found in the ejaculate of infected monkeys* (Miller et
al., 1992). Few other studies, however, provide direct evidence
of the ability of nonoxynol-9 to prevent viral transmission.
In the last five years, there have been only a handful of
studies designed to test directly whether nonoxynol-9 helps
prevent the sexual transmission of HIV in human beings. The
results of these studies are mixed and contradictory. A recent
study of sex workers in Cameroon, for example, found that women
who consistently used nonoxynol-9 suppositories reduced their
* This represents a 100 percent infectious dose in this model.
50

risk of seroconversion by 80 percent compared to infrequent users
(Zekeng et al., 1991). This effect persisted after controlling
for condom use, average number of partners per week, and other
potentially confounding factors. This observational study,
however, could not exclude the possibility of significant
selection bias. It is possible that the self-selected group of
women who consistently used the spermicide suppositories also had
in common some confounding characteristic not measured or
controlled for in the study that protected against HIV
seroconversion.
In a similar study among discordant couples in Zambia,
researchers have also documented a protective effect from
nonoxynol-9. Consistent use of nonoxynol-9 suppositories
resulted in a 40 percent decrease in HIV transmission to
seronegative women. Again the possibility of selection bias
cannot be ruled out (Feldblum, 1992).
The two studies above, which suggest that nonoxynol-9 does
offer protection from HIV, contradict a randomized controlled
trial among female sex workers in Nairobi that found that daily
use of the nonoxynol-9-impregnated Today® sponge appeared to be
associated with increased risk of HIV seroconversion (Kreiss et.
al., 1992). In 1987, Kreiss and colleagues enrolled 138
prostitutes in a clinical trial and randomly assigned 74 to
receive the nonoxynol-9-impregnated sponge and 64 to use a
placebo suppository. All of the women received intensive
counseling on the importance of using condoms in addition to the
sponge or placebo, and all were given a free supply of condoms.
In July 1990, however, the trial was stopped, because women using
the sponge appeared to have a higher rate of HIV seroconversion
than did the placebo controls. Further analysis revealed that
the risk of seroconversion for sponge users was almost twice that
of women using the placebo (hazard ratio of 1.7 with a 95 percent
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confidence interval of .9 to 3).* In addition, sponge use was
associated with a 3.3-fold increased risk of genital ulcers and
vulvitis, leading the authors to postulate that perhaps the
frequent use of high-dose nonoxynol-9 increased a woman's risk of
seroconversion by causing local lesions that allow the virus to
enter the body more freely.
Not surprisingly, these results (which were first reported
several years earlier than the Cameroon or Zambian studies) put a
pall over further research into the possible usefulness of
nonoxynol-9 in the fight against AIDS. Given the conflicting
data, some commentators have concluded that spermicides should
not be recommended to women for HIV prevention in the absence of
clear evidence of preventive efficacy (Bird, 1991). Others argue
that it is premature to dismiss nonoxynol-9, because the Kreiss
study had design limitations that rendered its results
inconclusive (Gollub and Stein, 1992; Voeller, 1992). Gollub and
Stein, for example, point out that the Today® sponge used in the
Kreiss study had an extremely high dose of nonoxynol-9 (1000
mg/ml) compared to other nonoxynol-9-containing products, such as
vaginal creams, gels, or film, which usually contain 350 mg/ml of
nonoxynol-9 or less. Also, the placebo group in the Kreiss study
used a vaginal suppository instead of a placebo (no spermicide)
sponge. Gollub and Stein further speculate that the irritation
and ulcers could have been a function of the high dose or the
sponge itself rather than of nonoxynol-9 per se. Also puzzling
was Kreiss' finding that the increased ulcers were found on the
vulva, not the vagina or the cervix, where one might expect to
find lesions created by an intravaginal sponge.
In an editorial accompanying the publication of the Kreiss
findings, Stone and Peterson further suggest that the increased
*
A Data Safety and Monitoring Committee recommended stopping
the study in July 1990 because the HIV seroconversion data
available at that time, although not statistically significant,
were inconsistent with any clinical benefit from nonoxynol-9
(Kreiss et al., 1992).
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ulceration could be the result of selection bias (Stone and
Peterson, 1992). Even though an attempt was made to assign
subjects randomly to use the sponge or placebo, the women in the
sponge group had a significantly greater prevalence of genital
lesions (16 percent) at baseline than did women in the control
group (3 percent). This finding may indicate that sponge users
differed from the placebo group in regard to some important
factor unmeasured by this study, such as the frequency of their
exposure to partners with other, unrecognized, STIs. Such an
unmeasured confounding variable might account for the increased
incidence of ulcerative lesions and/or HIV seroconversion
observed.
Since this early work, a number of studies have explored
further the impact of nonoxynol-9 on the vaginal mucosa.
Evidence has emerged to suggest that the
epithelial irritation
and disruption caused by nonoxynol-9 may be dose-dependent,
raising the possibility that it may be an appropriate HIV
prevention strategy for some women under more typical use
conditions (i.e., the infrequent application of low-dose
preparations), but not for high-frequency users, such as sex
workers. In one study of high-frequency use, for example, women
in Thailand were asked to insert four (150 mg) nonoxynol-9
suppositories a day for 14 days without having intercourse. Six
of the 15 women experienced epithelial disruption of the cervix
or vagina (Niruthisard, Roddy, and Chutivongse, 1991). In two
other clinical trials conducted in Cameroon and Thailand,
however, nonoxynol-9 suppositories, film, or gel (all containing
100 mg/ml or less) were not shown to damage the vaginal mucosa or
cause genital ulcers (Zekeng et al., 1991; Niruthisard et al.,
1991). Another study from the United States found no increased
disruption or vaginal irritation among women using nonoxynol-9
under average conditions (five to eight times a month) (Louv et
al., 1988).
Perhaps the most convincing evidence of a dose-related
response comes from a study recently completed in the Dominican
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Republic (Roddy et al., 1992). The study compared four groups of
users to a placebo control: women who used nonoxynol-9
preparations every other day, once a day, twice a day, and four
times a day. Researchers found that women using nonoxynol-9
every other day had no more epithelial disruption than did women
using the placebo; those using these preparations once or twice a
day experienced slightly more than twice the disruption (2.6 and
2.1 times); and those using them four times a day experienced
five times the incidence of mucosal damage compared to the
controls.
These results suggest that, to the extent that nonoxynol-9
does cause mucosal inflammation, micro-ulcerations, or sores, the
effects may be limited to situations of high-dose and/or highfrequency use. What remains to be established is whether
nonoxynol-9 offers women measurable protection from HIV in
typical use and at what point the negative consequences of
potentially disrupting the epithelium outweigh the positive
benefits of killing the virus. It is impossible to say at this
point whether a woman's risk of HIV transmission is lower in the
situation where there is a totally intact vaginal epithelium and
a high dose of live virus, or a low dose of live virus with some
epithelial disruption.
Given the incomplete and conflicting evidence on the
efficacy of nonoxynol-9, public health officials have disagreed
on what should be the appropriate message to women regarding
nonoxynol-9 use and HIV risk (Bird, 1991; Rosenberg and Gollub,
1992; Voeller, 1992; Rekart, 1992). In most instances, health
officials have abdicated responsibility for this matter by
remaining silent. The New York State Department of Health,
however, has recently developed a policy that recommends a
hierarchy of protection options for women (New York State Health
Department, 1992). When abstinence or a condom are not feasible,
the protocol suggests that women use a diaphragm and a vaginal
spermicide containing nonoxynol-9. As a last resort, the policy
suggests that women use nonoxynol-9 alone, although it makes
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clear that this offers the lowest degree of potential protection.
Such a policy recognizes the limits women often face in
negotiating condom use. Given these limits, many women have
already come to rely on various preparations of nonoxynol-9 as
their primary HIV prevention strategy (Vermund, 1992).
Clarifying the safety and efficacy of nonoxynol-9 for preventing
the sexual transmission of HIV, therefore, must be a highpriority research area.
D. Other Spermicides

There are a number of other spermicidal compounds that have
potential activity against HIV, as well as a range of other
sexually transmitted infections. These compounds include
octoxynol-9, benzalkonium chloride (Chermann et al., 1987;
Wainberg and Bleau, 1987; Wainberg et al., 1990), Betadine®
(Harbison and Hammer, 1989), chlorhexidine (Chantler, 1990;
Chantler, 1992, Harbison and Hammer, 1989), menfegol, and
gossypol (Polsky et al., 1989; Segal and Ueno, 1989). Of these
compounds, only octoxynol-9 is approved in the U.S. for use as a
spermicide. Benzalkonium chloride and chlorhexidine are approved
as spermicides in the United Kingdom. At present, only in vitro
data are available to suggest that these compounds may have the
potential to be useful as microbicides. Recently, menfegol was
used in a phase I trial in Senegal to assess toxicity. This
trial had to be stopped early because a very high rate of
inflammation and ulceration was observed (Laga, 1992b). Some
evidence exists that chlorhexidine may provide better penetration
into cervical mucous and retain a greater spermicidal activity
once in cervical mucous than other spermicides, suggesting it
could be a more effective spermicide (Sharman et al., 1986).
The importance of these data for preventing HIV infection is
unknown, given current uncertainties about the precise biological
mechanisms of HIV transmission. A new contraceptive sponge has
recently been developed (to be marketed under the name
Protectaid®) that incorporates low concentrations of both
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nonoxynol-9 and benzalkonium chloride (AXCAN, 1992). Product
information for this new sponge suggests that it has the ability
to rapidly inactivate HIV-1 in vitro. No data from clinical
tests are presented, however. Regarding gossypol, Segal and Ueno
(1989) have reported on the characteristics of a preparation that
might be tested as a vaginal protective cream for spermicidal and
virucidal activity. A recent report of the ability of orally
administered gossypol to eliminate HIV from the semen of HIVinfected men provides circumstantial evidence of its probable in
vivo efficacy (Garza-Flores et al., 1992).
In addition, a considerable amount of effort is going into
the in vitro screening of new compounds that are potentially
microbicidal. In 1992, for example, the Contraceptive Research
and Development (CONRAD) Program, a cooperating agency of USAID,
assayed 131 potentially spermicidal products (40 new experimental
formulations of nonoxynol-9, along with 91 materials containing a
different potentially active ingredient). Fifty-six of these
compounds were tested for activity against HIV in vitro, and 26
of them proved to be active. Several of these compounds are
currently being evaluated in rabbit models for vaginal irritation
and fertility effects. In vivo tests for antiviral activity have
not yet been initiated (Doncel, 1992).
E. Other Barrier Methods

There are no data concerning the ability of other existing
barrier methods (e.g., a diaphragm or cervical cap) without
spermicide to prevent HIV infection, since these methods are
usually recommended for use with a spermicide. There is,
however, some evidence that the cervical cap may be effective as
a contraceptive in the absence of spermicide (Richwald et al.,
1989). Also, in a recent study of diaphragm acceptability in
Brazil, investigators found that the lowest pregnancy rates
occurred at the one clinical research site where women were
counseled to use a diaphragm around the clock without spermicide
(Ferreira, 1992). In interpreting these results, it was
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suggested that when used in this manner, the diaphragm became a
noncoitally-dependent method and, therefore, had a greater useeffectiveness as a method of contraception. These findings may
have some relevance for women seeking to avoid cervical
infections, such as gonorrhea and chlamydia, in situations where
they cannot use a condom or spermicide. These data are probably
of limited relevance for HIV prevention, however, given evidence
that HIV transmission can occur through vaginal mucosa in the
absence of a cervix (Alexander, 1991).
V. CHALLENGES FOR FUTURE DEVELOPMENT OF MICROBICIDES

Despite the rapidly increasing number of women infected with
HIV and the inability of many women to negotiate condom use
successfully with their male partners, there has yet to be an
adequate mobilization of effort and resources for the development
of prevention methods that are under the personal control of
women. More than a decade into the global AIDS epidemic, we
still do not have answers to some of the most basic questions
regarding the biology of heterosexual transmission (Alexander,
1990; Forrest, 1991). We still do not know what to counsel women
with respect to the safety and microbicidal efficacy of vaginal
spermicides. And there has been virtually no discussion of the
serious need for a microbicidal compound that allows conception.
Why have the needs of women been overlooked? The answer
lies in a complex interplay between gender bias within the
medical research community and the entrepreneurial factors that
drive private-sector investment. It is now well documented, for
example, that the health concerns of women have received far less
than their fair share of public-sector research dollars (Society
for the Advancement of Women's Health Research, 1991). In fact,
only recently has the research establishment begun to acknowledge
that women are at substantial risk of HIV (Correa, 1992).
The neglect of microbicide research in the public sector has
been matched by an even greater disinterest among private
pharmaceutical companies. Microbicides are largely perceived as
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not profitable, due to the difficulty in securing patent
protection for such products and an extremely complex regulatory
environment. Companies also fear the costly product-liability
suits that may result from a compound's inability to provide
complete protection from a fatal disease despite cautionary
product labeling, as well as litigation related to alleged lowlevel associations with birth defects. This latter issue has
occasionally threatened the availability of vaginal spermicides,
such as nonoxynol-9 (Mills et al., 1982; Shapiro et al., 1982).
As a result, the development of a microbicide active against HIV
infection will require a concerted public-sector research and
development effort. This has long been the case with new
contraceptive technologies (Bardin, 1987; Mastroianni, Donaldson,
and Kane, 1991; Harr and Johnson, 1991).
There is an urgent need for the further testing of existing
compounds and devices, as well as the innovative search for
newer, less toxic microbicidal compounds. Ideally, this latter
effort would include the identification of both contraceptive and
noncontraceptive preparations. The following discussion outlines
some of the salient issues pertaining to the development of
vaginal microbicides within the personal control of women.
A. Biological Issues

A broad range of basic scientific issues relates to the
development of new microbicidal compounds for preventing the
sexual transmission of HIV. These range from understanding the
chemical and physical properties of potential microbicides and
product formulations, to defining more precisely the exact
biological mechanism of HIV transmission. Although a
comprehensive review of such issues is beyond the scope of this
paper, this section will highlight some of the most prominent
concerns.
Despite a considerable amount of research effort, much
remains to be learned about the basic biology of sexual
transmission of HIV (Alexander, 1990; Alexander et al., 1990).
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Epidemiological studies suggest that a person is most infectious
both very early and very late in the course of his or her
infection. During the period immediately following infection, a
person experiences high levels of virus in the blood and bodily
secretions prior to the development of anti-HIV antibodies
(Goudsmit et al., 1987; Stramer et al., 1989). Advanced
infection is also associated with high levels of infectiousness,
a phenomenon that mirrors the decline in measurable immune
function (Osmond et al., 1988). Recent studies of HIV-infected
men show that HIV is more commonly found in the semen of men with
advanced infection (Anderson, 1992) .
HIV-infected lymphocytes and macrophages are primary
infectious elements in semen (Alexander, 1990; Anderson, 1992).
These immune cells are abundant in normal semen and have been
shown to increase in the presence of genital tract inflammation
(such as that resulting from common STIs) and HIV infection
(Wolff and Anderson, 1988). Significant amounts of cell-free
virus have also been found in semen (Borzy, Connell, and
Kiessling, 1988; Krieger et al., 1991; Anderson et al., 1992).
Discerning whether HIV transmission involves cell-associated
virus, cell-free virus, or both, is a critical question for
microbicide development. For example, if it were convincingly
demonstrated that only virus associated with immunologically
competent cells, such as lymphocytes and macrophages, was capable
of infecting the female reproductive tract, this would have
significant implications for the types of microbicidal compounds
one would pursue. In such a scenario, the virucidal action could
target the infected host cells instead of the virus itself.
Some recent evidence suggests that cell-associated virus is
a principal means of HIV transmission. Phillips and coworkers at
the Population Council's Center for Biomedical Research have
developed an in vitro model of viral transmission using a
confluent epithelial cell culture (Bourinbaiar and Phillips,
1991;.Phillips and Bourinbaiar, 1992; Phillips and Tan, 1992).
In this model, HIV did not become associated with the epithelium
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after exposure to cell-free virus. When the test was repeated
with HIV-infected CD4 lymphocytes, however, these lymphocytes
were soon observed in close association with the epithelial
surface. Subsequent observation by electron microscopy
demonstrated the directional release of mature viral particles
into the space between the lymphocyte and epithelium, as well as
the rapid uptake of virus by the epithelial cells. It is also
well established that Langerhan's cells are present in the vagina
and cervix and could be recipients of cell-free or cellassociated HIV (Hussain et al., in press; Edwards and Morris,
1985). These observations obviously do not exclude a role for
cell-free virus in the transmission of HIV, however, and
therefore require corroboration with in vivo studies of viral
transmission.
Speculating from the above, one possible scenario is that
cell-associated virus is primarily responsible for transmission
across intact epithelial surfaces, but that cell-free virus can
infect mucosa when present in high concentration or when
epithelial surfaces are disrupted.* Studies of discordant
couples, for example, have demonstrated that older/postmenopausal
women are at increased risk of HIV seroconversion (Peterman et
al., 1988; European Study Group, 1992), a finding attributed to
their increased risk of epithelial disruption during sex due to
low estrogen levels and atrophic vaginal mucosa.** This may
also partially explain why HIV transmission is augmented in the
presence of genital ulcerative diseases that result in mucosal
disruption (Quinn et al., 1988). Further, this explanation might
help with interpreting the conflicting data reviewed above
regarding the safety and efficacy of currently available vaginal

*Data from monkey studies show that transmission can occur
when high concentrations of cell-free virus are nontraumatically
inoculated intravaginally (Miller et al., 1989)
**Others speculate that this could be a pH effect (Voeller and
Anderson, 1992a, 1992b).
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spermicides in preventing HIV infection. Given the nonselective
detergent properties of compounds such as nonoxynol-9, there may
be a narrow range between "enough" microbicidal spermicide and
"too much."
This line of reasoning suggests the need to develop more
specific intravaginal compounds that prevent the attachment of
HIV-infected lymphocytes to epithelial surfaces, the secretion of
virus from these cells, or the uptake of virus by the mucosal
epithelium, without indiscriminantly disrupting cell membranes.
One such compound may be dextran sulfate, one of a class of
polyanionic polysaccharides. Dextran sulfate has been
demonstrated to inhibit HIV replication in vitro (Bagasra and
Lischner, 1988). It has also been shown to inhibit the cellassociated transmission of HIV using the in vitro epithelial cell
culture model described above (Pearce-Pratt and Phillips, 1992).
This activity has been demonstrated at concentrations 100-1000
times lower than those associated with significant cytotoxicity.
The hypothesized mechanism of action of these polyanionic
compounds is that, by coating the epithelial surface with a
highly charged macromolecular film, they may physically repel HIV
and HIV-infected cells from the epithelium and thereby prevent
the directional release of HIV that occurs when these infected
lymphocytes attach to mucosal cells. As nondetergent compounds,
polyanionic polysaccharides should have considerably less local
toxicity than existing vaginal spermicides and may potentially
allow conception, since they have little effect on sperm
(Phillips, 1992). It should be emphasized, however, that
although this is certainly a promising class of compounds to
begin evaluating, no clinical data currently exist regarding
their safety or effectiveness for intravaginal use in preventing
HIV transmission.
Another basic issue related to the biology of HIV
transmission is our incomplete understanding of the precise cells
and tissues within the female reproductive tract that are
infected in the course of transmission. Disruptions of
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epithelial surfaces probably augment susceptibility to infection,
but data from animal models, as well as case reports of
infections acquired during artificial insemination, indicate that
such disruption is not required for transmission to occur (Miller
et al., 1989; Stewart et al., 1985). The work of Bourinbaiar and
Phillips suggests that cell-associated virus may infect typical
mucosal cells. But, does this happen throughout the vagina? Is
the cervix a more or less susceptible site? What is the role of
the upper genital tract structures, if any? Recent studies of
SIV transmission in hysterectomized macaque monkeys suggest that
the presence of a cervix is not required for transmission
(Alexander, 1991). Given the limitations of simian animal
models,* however, this finding may not easily generalize to
humans and, even if applicable, does not exclude an additional
(and potentially more important) route of infection via the
cervix or upper genital tract. Answers to such questions of
basic biology are essential to understand fully the interactions
of various contraceptive methods with HIV infection, as well as
the possibility of identifying a noncontraceptive microbicide
(Alexander, 1990; Cates and Stone, 1992).
Another important issue that bears directly on the
feasibility of developing a noncontraceptive microbicide is the
question of whether HIV infects or attaches to sperm. Several
authors have suggested that HIV may become associated with sperm,
either by attaching to the surface or crossing the cell membrane

*
Because of the relatively low probability of infection
resulting from a single exposure, the simian models of SIV
transmission have depended on the identification of a "100 percent
infectious" dose of SIV (i.e., the concentration of SIV that, when
introduced intravaginally, results in infection in all cases)
(Miller et al., 1989). This dose is approximately 1,000 times the
usual concentration of SIV in macaque semen. When this dose was
used in macaques following surgical removal of the uterus,
infection was noted to occur (Alexander, 1991). Whether or not
this model accurately reflects the transmission dynamics in
macaques under natural circumstances could be questioned, as well
as the generalization of this finding to humans.
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(Bagasra et al., 1988; Scofield, 1992). Others have refuted
these findings after failing to find a physical association
between HIV and sperm in careful assays used to separate motile
sperm from other elements of semen, as well as failure to
identify HIV DNA using genetic amplification techniques on the
sperm fractions of semen from more than 200 seropositive men
(Anderson, 1992). Current consensus favors the lack of a
significant relationship between HIV and viable sperm; but the
data are by no means complete, leaving open the possibility of an
uncommon, but perhaps biologically relevant association
(Anderson, 1991). Obviously, a significant association of virus
with sperm would make the development of a noncontraceptive
microbicide extremely problematic.
Emerging data further suggest that the complex chemical,
microbiological, and immunological environment of the male and
female reproductive tracts may play a major role in determining
the likelihood of HIV transmission. Understanding the ecology of
the vaginal environment is essential for future microbicide
development, because any compound introduced intravaginally has
the potential to disrupt the balance of vaginal flora, pH, or
immune function. For example, recent evidence has shown that the
normally low pH of the vagina may be virucidal in its own right
(Voeller and Anderson, 1992a,b). Voeller and Anderson have shown
that at pH levels below 5.5 both HIV and HIV host cells are
rapidly inactivated. Semen typically neutralizes the acidic pH
of the vagina. This finding suggests that a microbicidal
preparation should be formulated to include a strong acidic
buffer if feasible. It also raises the possibility of developing
a prevention strategy based on keeping the pH of the vagina low.
The disturbance of vaginal pH may also partially explain why
nonulcerative genital tract infections have been shown to augment
the transmission of HIV to women (Wasserheit, 1991). Vaginal
infections, such as trichomoniasis and bacterial vaginosis, are
very common and often remain unrecognized or untreated in many
women (Wasserheit, 1989). These infections are commonly
63

associated with an alkaline change in pH (Hillier and Holmes,
1989; Rein and Muller, 1989). This suggests that the routine
screening and treatment of women for these common reproductive
tract infections may help reduce HIV transmission, especially in
areas where heterosexual transmission predominates.
Another mechanism by which reproductive tract infections
augment women's susceptibility to HIV infection is by attracting
large numbers of potential "host cells" into the genital tract
mucosa through the inflammatory process. Data indicate that,
unlike semen, healthy female vaginal secretions contain
relatively few CD4 lymphocytes and macrophages, except during
menstruation (Anderson and Hill, 1991). Future preparations of
vaginal compounds for use as microbicides must take into account
effects on the vaginal flora. Disruption of the vaginal flora
might result in subclinical inflammation or pH alteration that
could potentially impair the natural defenses of the reproductive
tract. The potential for such effects, for example, have
recently been reported for nonoxynol-9 (McGroarty et al., 1990a;
1990b).
A final set of issues crucial to microbicide development
relates to the mucosal immunity of the male and female
reproductive tracts. In addition to the systemic immune defenses
of the body, most mucosal surfaces exhibit immune protection
against potential pathogens through the local activity of
immunologically competent cells and the secretion of antibody
that prevents primary infection of epithelial surfaces.
Currently, very little is known about the local immunity of the
reproductive tract (Forrest, 1991; Anderson and Pudney, 1992).
The data that do exist on women suggest that the mucosal
secretory immune system of the endocervix provides a primary
immune defense against lower reproductive tract pathogens,
primarily through the local production of Immunoglobulin A (IgA)
(Anderson and Hill, 1991; Rebello, Green, and Fox, 1975;
Underdown and Schiff, 1986) .
The majority of people acquiring HIV today are infected by
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mucosal exposure to cell-free or cell-associated virus through
heterosexual contact. The most pressing question, therefore, is
whether candidate vaccines, many of which are primarily targeted
to stimulate systemic immunity, will provide an adequate
immunological barrier at the mucosal surfaces of the reproductive
tract. Experience with other mucosal pathogens suggests that
there may be a fair amount of segregation between the systemic
and secretory immune systems. As highlighted in a recent review,
"systemic immunity alone may not be adequate to interrupt the
heterosexual transmission of HIV" (Forrest, 1991).
This uncertainty provides an important reason to pursue
microbicide development even in the face of possible advances in
vaccine research. While much insight has been gained through
vaccine research, it is clear that there are no extremely
promising pre-exposure vaccine candidates in the offing at
present (Harvard AIDS Institute, 1992). Further, most candidate
vaccines nearing clinical trials in humans may affect only
systemic immunity. Therefore, even if one of these should prove
effective against blood-borne transmission of HIV (e.g., through
sharing contaminated needles), there is no assurance it will
offer women protection against infection through vaginal
intercourse. Women may still need a microbicide even after the
first generation of vaccines becomes available.
Indeed, microbicide and vaccine research should be seen as
mutually reinforcing. It may turn out, for example, that to be
most effective, HIV vaccines will have to be administered
mucosally. Although it may be possible to consider administering
such vaccines orally, it may also turn out that such vaccines
would need to be delivered intravaginally, in which case
experience gained with microbicidal agents regarding vehicles for
their storage, formulation, and dispersal may be highly relevant.
Also, given that the design of clinical efficacy trials for
microbicides and vaccines share some important similarities,
there may be significant opportunity for combined or sequential
testing of these prevention technologies. For example, the
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vaccine trials branch of the National Institute for Allergy and
Infectious Disease is actively considering the benefits of
expanding its research infrastructure developed for vaccine
evaluation to include the testing of other prevention measures,
including microbicides (Vermund, 1992).
B. Issues of Clinical Testing

One of the most common concerns expressed about microbicide
development is that it would be impossible to design clinical
trials that are both scientifically valid and ethically
defensible. Although clearly a complex and costly endeavor, the
task of testing a candidate microbicide is both feasible and
considerably less problematic than testing a vaccine*. Below we
explore some of the more salient issues around the design of
clinical trials for a female-controlled microbicide.
Before entering human testing, a candidate compound would
go through standard testing for toxicity in rabbits and rats, as
well as efficacy evaluation in a simian species. With minor
modification (i.e., the addition of efficacy testing in a simian
species), the typical product-development sequence for a new
contraceptive could be applied to the pursuit of new microbicidal
compounds. The sequence of preclinical, animal testing required
for evaluation of new intravaginal compounds, as well as the
simian models for retrovirus transmission, are discussed
elsewhere and will not be reviewed here (Chvapil et al., 1980;
Miller et al., 1992). The preclinical evaluation of potential
compounds will obviously require serious attention to the
potential mutagenicity of vaginal compounds, especially those
that are noncontraceptive.
Following successful testing in vitro and in animal models,
a carefully selected group of potentially microbicidal compounds
*Vaccine evaluations will require the establishment of a
testing infrastructure that can answer the question of how long
immune protection lasts once established (i.e., how many months,
years, or decades of protection does a candidate vaccine provide?).
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would be brought to human trials. Human trials involve three
phases: Phase I trials evaluate the safety, toxicity, and
acceptability of a compound in a limited number of women; Phase
II trials generally involve 50 to 200 women and are designed to
establish some evidence of effectiveness; and Phase III trials
expand the safety and effectiveness testing to 1,000 or more
women. For a typical compound, completion of all three phases of
human clinical trials can take at least five years, but may take
longer for microbicide evaluation, given the sample size
requirements and special requirements of study populations
described below.
The challenge with respect to microbicide development is to
design an effectiveness trial that is both scientifically
rigorous and ethically defensible. From a scientific standpoint,
the most rigorous, and therefore the most desirable, design is a
randomized controlled trial (RCT), where trial participants are
randomly assigned to receive either the compound under
investigation or a placebo (or an "active control" if there
exists a compound with previously demonstrated effectiveness).*
Since it would be unethical to withhold a form of HIV prevention
known to be protective, participants in a microbicide trial would
also receive free supplies of condoms and be counseled to use
both the vaginal product and a condom during each act of
intercourse. Researchers would then use statistical techniques
to determine any incremental benefit offered by the experimental
compound over condom use alone (Figure 1). Many of the practical
issues of clinical trial design for evaluating the effectiveness
of spermicides in preventing more common STIs (including a
discussion of study population, site selection, and follow-up
procedures) have recently been reviewed (Foldesy et al., 1990).
If conducted today, the control group in a microbicide
trial would be a placebo formulation, since there is no convincing
evidence of an existing microbicidal agent that is both safe and
effective. One could also consider a three-armed study comparing
a new microbicide with nonoxynol-9 and placebo.
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Periodic review by unblinded data
safety and monitoring c o m m i t t e e

Figure 1: Research Design

This type of trial design raises important ethical issues.* One
of the most significant concerns in conducting an RCT is that, at
best, some members of the comparison group will become infected
with HIV while participating in the study. The critical ethical
question here, however, is whether all study participants will
benefit from participation in the trial. According to the
ethical principle of "beneficence," researchers have an
obligation to minimize harm and to maximize the benefits to all
trial participants (Table 6). In the optimal design, therefore,
all participants, including those in the control group, would
benefit from receiving condoms, reproductive health care, and
intensive HIV counseling. If the trial were performed properly
(i.e., if condom counseling were active and sustained), the women
in the control group should have a lower HIV seroconversion rate
than women not participating in the study. Historical controls
could be used to document improved use of condoms by all
participants as a direct measure of the benefit of participating
in the trial.**
To illustrate how this might work, consider the hypothetical
results laid out in Figure 2. Researchers randomly assign a

The analysis offered here is based on recent guidelines
developed to assist in the design of clinical trials of HIV
therapeutic agents and vaccines (Levine, Dubler and Levine 1991;
U.S. Public Health Service, 1991; Council for International
Organizations of Medical Sciences, 1991). It should be emphasized
that any clinical trials of new microbicidal compounds undertaken
by the Population Council, in either developed or developing
countries, would be under an investigational new drug (IND)
application to the U.S. Food and Drug Administration and would
follow the rigorous procedural requirements of this regulatory body
as well as be subject to its inspection and monitoring authority.
From a research perspective, there is a subtle disincentive
to promote condoms vigorously, because doing so decreases the power
of the study (i.e., it makes it more difficult to measure a
protective effect in the test compound). A direct measure of
benefit would therefore provide an important check, furnishing
measurable assurance of program effort to reduce the HIV infection
risk of all trial participants.
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group of sex workers with a seroincidence rate of 4 percent per
year to receive either the test compound or a placebo. In
addition, both groups receive extensive counseling and free
condoms, which raise their condom use from 10 percent before the
trial to 50 percent after. In the control group, the women's
seroincidence declines from 4 percent to 3 percent, a 25 percent
drop, whereas in the experimental group, the rate declines to 1.5
percent, a 62.5 percent drop. This design would confirm the
protective effect of the test substance while at the same time
reducing the rate of seroconversion in the control group.
The principle of beneficence also requires that no one be
refused access to a substance known to be protective. Applied to
microbicides, this means that randomization can only be justified
when there is a legitimate dispute as to whether the substance
under investigation is beneficial or not (Levine, Dubler, and
Levine, 1991; Freedman, 1987). A good case can be made that
nonoxynol-9 meets this criterion, given the conflicting data
available on its ability to protect women from HIV infection, and
the possibility that it may actually increase women's risk of
HIV. Hence, a randomized control trial of nonoxynol-9 at low or
moderate doses would be justified to settle the existing debate
over its effectiveness. It may be necessary, however, to delay
effectiveness trials in high-frequency users until further
Table 6:

Definition of Ethical Principles

Respect for Persons; Respect for persons incorporates at least
two ethical convictions: first, that individuals should be
treated as autonomous agents, and second, that persons with
diminished autonomy are entitled to protection. The notion
of "informed consent" derives from this principle.
Beneficence: Two general rules have been formulated as
complementary expressions of beneficent actions - 1) to
minimize harm; and 2) to maximize possible benefits.
Justice: Justice refers to the equitable distribution of both
the burdens and benefits of research.
Source:

(Levine, Dubler, and Levine, 1991)
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toxicity data become available regarding the safety of nonoxynol
9 in various doses and formulations.
A final justification for a randomized control trial is the
need to have the highest degree of scientific certainty possible
in the results of a clinical trial of potential microbicides. A
less than rigorous trial (i.e., a poorly controlled study) would
leave women, counselors, and program directors in a nebulous
position not unlike the uncertainty they face today regarding the
effectiveness of nonoxynol-9. Presently, decision-makers are
forced to make policy in the absence of clear scientific data,
potentially exposing women to unnecessary risk. Likewise, an
inconclusive trial would complicate further research: If results
"suggested" that a compound were protective, it would be
difficult to identify an appropriate control group for future
trials. There is, therefore, a strong ethical imperative to
design trials that are scientifically, as well as ethically,
rigorous.
Researchers would have to undertake a variety of other
safeguards to guarantee the ethics of microbicide trials. Among
them is the need to ensure informed consent, an imperative that
derives from the ethical principle of "respect for persons" (see
Table 6). Informed consent requires both the absence of direct
or structural coercion and full disclosure of trial procedures,
including the randomization process and the use of a placebo if
applicable. With respect to microbicide testing, this would
require that counseling, condoms, and reproductive health care be
made available to women who choose not to be in the trials (as
well as to participants), so that women would not feel obliged to
participate just to gain access to these often scarce resources.
Also, researchers would have to take special care to ensure that
women understood the contraceptive activity of both the test
substance and the control. Some women may wish to protect
themselves further from pregnancy during the trial, while others
may choose not to participate if doing so might prevent them from
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conceiving.* Discussing the issue of contraceptive activity is
especially important in settings where access to abortion is
restricted by law or by lack of services.
A relatively new aspect of the ethics of clinical-trial
design that has gained currency during the AIDS era is the need
to invite community participation in trial design (Levine,
Dubler, and Levine, 1991). In the case of microbicides,
"community consultation" would mean soliciting input from both
the community of women actually involved in the trial as well as
from women's health advocates. Also critical is the
establishment of an independent, unblinded, "safety and data
monitoring committee" that can periodically review the progress
of the study and recommend its early cessation if the
experimental compound proves either clearly beneficial or clearly
detrimental to the trial participants before the planned
termination of the study.
Perhaps the most difficult ethical issue, however, derives
from the principle of justice, which mandates that the burdens
and benefits of research be equitably distributed (Levine,
Dubler, and Levine, 1991). A particularly gross example of
injustice would be where a new vaccine is extensively tested in
sub-Saharan Africa, but once proven, is unavailable to Africans
due to its high cost (Freedman, 1992; Ndinya-Achola, 1991). This
precise example has been the focus of much debate, given the high
cost of vaccine development, the prominence of private-sector
interest, and the long-term investment that would be required to
make vaccines available in many developing countries.
There are a variety of scientific exigencies that make it
almost certain that phase III testing of a microbicide would have

It is also possible, especially in the case of new
compounds, that complete data on contraceptive efficacy might not
be available at the time of preliminary evaluation for microbicidal
efficacy. In this event, initial tests would need to be conducted
with women who have been sterilized or are otherwise protected from
unwanted pregnancy.
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to take place primarily in the third world. Two preconditions
are required to measure a significant decrease in HIV
seroconversion attributable to an effective microbicide:
1.

A population of women with a high seroincidence rate
attributable primarily, if not exclusively, to the
sexual transmission of HIV;* and

2)

A sufficiently large study population to achieve
statistical significance.

As Table 7 illustrates, the number of trial participants required
to achieve statistical significance quickly becomes unmanageable
in populations with annual HIV seroincidence rates of less than 2
to 4 percent.** For example, the number of participants
required in each arm of a clinical trial seeking to establish 50
percent efficacy of a test compound in three years drops from
3,039 women to 743 women as the seroincidence of the study
population increases from 1 to 4 percent (Table 7). Note that
even at a high seroincidence rate of 4 percent, however, it is
likely that data from multiple sites would have to be pooled for
analysis. As with vaccine evaluations, the greatest chance for
success lies in the design of multicenter, multicountry studies
that include both developed and developing country populations of

*
It is important to avoid any study effect that may result
from "contamination" with other routes of transmission, such as
injection drug use.
Compared to sexual transmission, it is
relatively easy to become infected through parenteral exposure;
hence, any significant contamination could potentially obscure the
effects of the product under study or greatly increase the required
sample size.
** Active program effort to reduce HIV transmission through
means other than microbicide use has the effect of significantly
increasing the required sample size for a clinical effectiveness
trial.
The required increase in sample size is directly
proportional to the success of these alternative interventions.
Sample size calculations, therefore, should be made from estimates
of the seroincidence that can be expected in a given study
population after the initiation of such alternative intervention
strategies.
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women.
Study populations that fit the criteria outlined above are
found more commonly in the developing countries and often involve
vulnerable women, such as sex workers, who are subject to
economic and physical exploitation.

Although there are

populations of women with annual seroincidence rates in the range
of 2 - 3 percent in the United States (e.g., in the major urban
centers of New York and New Jersey), a large proportion of these
women are injection drug users, making them less ideal for
Table 7 - Number of Participants Required for Microbicide Trials
Effectiveness
Annual HIV Seroincidence
____________
____ L_%________ 2%________ 3% _____ 4%
7,061
14,376
9,499
25%
29,008
9,677
6,396
4,755
30%
19,521
1,486
3,016
1,996
50%
6,078
1,268
840
626
2,552
70%
556
369
276
1,118
90%
322
214
160
646
99%
Assumptions: Alpha = 0.05, 1 - Beta = 0.90, 2-tailed test
N = total sample size, two-armed study
3 year trial (participants enrolled for 2 years and
followed for 1 year each.) No loss to follow-up.
For formula see Cohen, 1977.
microbicide testing because of their risk of acquiring infection
through nonsexual means. Clearly, the political and ethical
questions raised by this reality would have to be resolved prior
to initiating Phase III testing. If the developing world is to
bear the major burden of clinical research related to
microbicides, women in developing countries must realize the
benefits of such compounds once proven. Similar concerns about
the distributive justice of vaccine testing are currently under
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debate and may provide some guidance in this important area.
The issues of North/South equity raised by microbicide
testing may be slightly less charged than those raised by
vaccines, because the distribution of an effective microbicide,
while requiring attention to manufacturing, storage, and
transportation logistics, would not necessarily depend on
extensive health-system support. There is some reason to expect
that these compounds, once proven, could be incorporated into
existing condom-distribution systems and social marketing
campaigns. Even though, as described above, microbicide
development will most likely depend on a public sector-supported
research effort, efficient manufacture and distribution will
require some degree of profitability. Therefore, the major
challenge (as with condom supplies today) will be identifying
resources to finance the recurrent costs of commodity procurement
and distribution. In many places, this will require substantial
infrastructure development, as well as the political will to
provide public subsidy for the purchase and distribution of these
commodities for individual use in the public good.
A final ethical question concerns the appropriate study
populations to use in Phase I safety testing. Since studies on
safety, tolerance, and absorption can be done in populations not
at significant risk of AIDS, there is little justification for
doing Phase I research among vulnerable populations.* Special
caution should be applied in the recruitment of sex workers from
developing countries for Phase I trials. Given the economic,
political, and violent realities of many of these women's lives,
it is impossible to ensure (even through cash payments) that they
will not "work" during the trial, thereby exposing themselves to

*
There are compelling reasons to repeat Phase I safety and
toxicity testing in developing countries and among high-risk women
following the initial testing in the country of origin and the
accumulation of adequate safety data in low-risk populations. The
U.S. National Institutes of Health, for example, has adopted this
policy for Phase I testing of candidate vaccines (Vermund, 1992).
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HIV while using an intravaginal compound whose safety in humans
has not yet been demonstrated. Preferably, Phase I trial
participants should not be at risk of contracting HIV during
initial safety and acceptability testing.*
C. Programmatic Issues

In addition to the challenges of designing ethical and
scientifically valid clinical trials, a number of important
programmatic issues must be considered in relation to microbicide
development.
Perhaps most important is a commitment to seeking
women's input at each stage of the research and development
effort. Soliciting women's needs and preferences at the outset
will help ensure that the product, once developed, will be used
and accepted. The importance of this type of consultation for
contraceptive development has recently been summarized by the
International Women's Health Coalition and the World Health
Organization's Special Programme of Research on Human
Reproduction in their publication entitled "Creating Common
Ground: Women's Perceptions on the Selection and Introduction of
Fertility Regulation Technologies" (1991) .
Women's input is especially critical with respect to the
initial design criteria for a new microbicidal product. Table 8
lists some of the dimensions along which a new product might
vary. In all likelihood, a broad range of product formulations
will ultimately be necessary. The ideal formulation for an
adolescent in the United States, for example, might be quite
different from that required by a married woman in rural India.
An important step in product development will be to conduct field
research to establish women's needs and preferences in different
geographic and cultural settings.

We gratefully acknowledge the help of Priscilla Alexander at
the WHO Global Programme on AIDS in articulating this important
point.

Table 8: Some Dimensions of Microbicide Product Specification
Contraceptive activity
Interaction with existing contraceptive use
Capacity for covert use ("detectability")
Method of application (e.g. jelly, film, etc.)
Coital dependence
Postcoital effectiveness
Onset and duration of action
Spectrum of microbicidal activity
Disposability
Affordability
Smell/taste
Messiness
Shelf life
Stability at room temperature
Ease of insertion
Appropriateness for anal/oral sex
Experience from testing the acceptability of various
contraceptives suggests that one of the more critical design
features for microbicide development will be its method of
application. A microbicidal compound could be manufactured in a
number of ways, each with unique implications for its
acceptability among users. Cultural factors, for example, might
affect whether women would prefer a vaginal cream applied with an
applicator or a vaginal sponge inserted by hand. In parts of
Africa, for example, women use a variety of astringent substances
to dry and tighten the walls of the vagina before sex (Dallabeta
et al., 1990). Where this form of "dry sex" is common and
preferred, a moist vaginal creme would probably receive little
use.
Fortunately, there is great potential for improvement in the
design of new delivery vehicles. One approach that holds much
promise is the adaptation of the contraceptive vaginal film
(CVF), a delivery vehicle for nonoxynol-9 now gaining currency.
These films, which resemble small squares of cellophane, dissolve
rapidly when inserted into the vagina and wash away with body
fluids (Hatcher, 1992). That they can be easily hidden and
stored and are not "messy" like foams and jellies also make them
a potentially surreptitious method. This fact should make the
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films especially attractive to women who are afraid or unwilling
to broach the subject of HIV protection with their partner.
Contraceptive research also suggests that the timing of
insertion will be another factor critical to the acceptability of
new microbicidal products. Couples tend to prefer methods that
do not interrupt the spontaneity of intercourse, a property
determined in part by the product's onset and duration of action.
Microbicidal products that become effective quickly and/or that
can be inserted long before intercourse are likely to be
preferred. A great need also exists for a product that could be
used postcoitally to protect women subject to nonconsensual sex.
It is reasonable to expect, given our current understanding of
HIV transmission, that a product could be developed that would
offer at least some protection if administered immediately after
intercourse. The need for such a product is evidenced by the
reality that some rape crisis centers in the United States have
been using nonoxynol-9 for this purpose, although there are no
data substantiating its efficacy when used in this manner
(Dattel, 1992). A postcoital method might also have some utility
for women, especially adolescents, in communities where
"planning" to have sex is unacceptable (Pick de Weiss et al.,
1991) .
Another set of programmatic issues revolves around the
introduction, distribution, and postmarketing surveillance of any
new microbicidal product. The development of appropriate
information, public education, and counseling materials must
complement the development of any new biotechnology to ensure
that women realize the maximum benefit of such new products and
that providers supply proper guidance regarding correct usage. A
major advantage of a microbicide over a vaccine is that it could
be distributed and sold through existing commercial channels
rather than be dependent on health-care workers and an already
overburdened health-care system. Vaccines often require delicate
handling, constant refrigeration, and trained personnel, making
vaccine programs considerably more difficult to administer than
79

distribution networks based on commercial marketing. Several
decades after the development of a highly effective measles
vaccine, for example, measles remains one of the most common
causes of child mortality (UNICEF, 1992), a fact that speaks to
the difficulty of achieving coverage, given the virtual absence
of health services in many resource-poor areas.
By contrast, the programmatic challenge of microbicides will
be to adapt and apply the lessons learned from condom promotion
to a new product targeted to women. In many cases, microbicides
could potentially be incorporated into the same procurement,
storage, and distribution systems presently used for condoms.
Moreover, many of the same social-marketing techniques used to
create demand for condoms could also be used to promote
microbicides. Even in very poor countries like Zaire, socialmarketing campaigns have been able to increase greatly the sale
of condoms using a skillful mix of media, packaging, pretested
slogans and ads, and aggressive, widespread distribution through
multiple outlets (Population Services International, 1992b).
Also promising are opportunities to distribute and promote
microbicides through family planning programs, mothers' clubs,
and other women's organizations. Indeed, for this type of
product, word-of-mouth, "woman to woman" promotion may be the
most effective.
CONCLUSION

We can no longer ignore the urgent need to develop an
expanded range of female-controlled options for HIV prevention.
The discovery and testing of both contraceptive and
noncontraceptive compounds for intravaginal use in preventing the
sexual transmission of HIV and other STIs, as well as further
evaluation of existing spermicidal compounds, should command a
high priority for immediate research. The information reviewed
here suggests that this is a difficult, yet feasible, challenge.
The development and testing of microbicidal compounds will
require advancing our basic understanding of human reproductive
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biology. It will rely on careful attention to the ethics of
clinical trial design and require a lasting dialogue between
scientists and advocates. And it will require the collaboration
of professionals from various academic disciplines, as well as
the coordination of efforts among various governmental,
nongovernmental, and intergovernmental organizations.
The world is waiting for the development of these compounds
as an important addition to the global campaign against the
spread of AIDS. And, the world will not wait patiently. The
AIDS epidemic has precipitated a new type of social activism.
Persons living with HIV infection, as well as communities at
risk, have organized and begun to demand an accountability from
the scientific community that is without precedent. Activist
organizations have articulated specific demands regarding access
to experimental therapies, the design of clinical trials, the
allocation of research funds by governmental agencies, and the
generation of research funds themselves. This activism has begun
to shape and accelerate the global response to AIDS.
As recognition has grown concerning women's risk of HIV
infection and the limitations of the current AIDS strategy,
women's health advocates have begun to advocate for more research
in this important area (Juffer, 1992; International Women's
Health Coalition, 1992). At a meeting held in Barbados in March
1992, cosponsored by the International Women's Health Coalition
and the Women and Development Unit of the University of Barbados,
West Indies (WAND), leading women's health advocates from over 40
countries outlined an agenda for future research regarding
women's health (International Women's Health Coalition, 1992).
This agenda included a strong call for the development of femalecontrolled microbicides.
In June 1992, the Population Council sponsored a meeting in
New York involving over 50 advocates and scientists from around
the world to outline the feasibility and challenges of
microbicide development. Our conclusion was that the development
of such technology was an achievable, if demanding, goal. The
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Population Council has subsequently taken steps to make
microbicide development a high-priority area for its technology
development program. Other organizations have also begun to
accelerate their efforts concerning this important endeavor.
Only a persistent and conscious neglect of women's needs
will explain continued inattention to this important area of
research. Fortunately, as the brief history of AIDS has taught
us, not only is the world waiting — history is watching.
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